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Abstract
Racial and ethnic disparities related to lung cancer treatments and outcomes are not fully
understood but may be due to individual or institutional factors. Following established
national cancer treatment guidelines may improve patients’ quality of life, outcome to
treatment, and facilitate the eradication of lung cancer. There are limited data on the realworld treatment of racial/ethnic groups with non-small cell lung cancer (NSCLC)
according to clinical practice guidelines, therefore this population-based cohort study
examined the receipt of first line treatment for advanced or metastatic NSCLC according
to the National Comprehensive Cancer Network (NCCN) practice guidelines. The Social
Cognitive Theory served as the framework as it focuses on individual cognitive
influences and self-efficacy. A retrospective analysis of NSCLC patients (> 65 years) was
conducted using the linked Surveillance, Epidemiology, and End Results (SEER) data
linked with Medicare. Logistic regression models were fit to evaluate the relationships
between patient race/ethnicity and the receipt of treatment according to the guidelines
within various clinical strata (e.g., histology type, stage of disease). There were no
significant differences between Caucasians and African Americans in terms of treatment
consistent with guidelines after controlling for other factors. One limitation to this study
was the administrative nature of the Medicare database and the limited number of
Hispanic patients. This research may contribute to positive social change by supporting a
deeper understanding of factors that might influence NSCLC treatment selection. Public
health initiatives to promote compliance with treatment guidelines can lead to better
outcomes following medical treatments, especially for NSCLC.
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Chapter 1: Introduction to the Study
Introduction
Lung cancer is the second most common cancer in the United States and is a
major health problem, representing 14% of all new cancers (American Cancer Society
[ACS], 2018). It kills more patients than breast cancer, colon cancer, and prostate cancer
combined (ACS, 2013; Lung Cancer Alliance, 2013, Surveillance Epidemiology End
Results [SEER], n.d.) and worldwide contributes to more deaths than HIV, tuberculosis,
and malaria (ACS, 2011). Lung cancer is a disease of the elderly. Two out of three
individuals with lung cancer are 65 years of age or older with a median age at diagnosis
of 70 years, and less than 2% of lung cancer are diagnosed in individuals younger than 45
years of age (ACS, 2014). In 2013, lung cancer was the leading cause of death in men
and women in the United States, killing over 160,000 individuals (ACS, 2013b;
American Lung Association [ALA], 2014, SEER, n.d.). The World Health Organization
(WHO) predicts the number of new cancers overall will grow from 14 million to more
than 22 million by 2030 (American Society Clinical Oncology [ASCO], 2014).
The incidence of lung cancer varies by stage of disease and by race/ethnicity.
According to the ALA (2010) African American men are diagnosed with lung cancer at a
37% higher rate than Caucasian men while Hispanics have an almost 50% lower
incidence of lung cancer as compared to Caucasians, in part due to less smoking (ACS,
2012). Overall, African Americans have a higher cancer incidence rate than other racial
and ethnic groups and a mortality rate that is approximately 30% higher than Caucasians
(ACS, 2013; ALA, 2010; Office of Minority Health, 2013, SEER, n.d.). The incidence of
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patients diagnosed with advanced stage IIIB lung cancer is 17.6% and 40% with
metastatic stage IV disease (National Cancer Institute [NCI], 2011).
The mortality rates for most major cancers such as colon, breast, and prostate
have been decreasing; however, the lung cancer mortality rate, though it has decreased
due individuals quitting smoking, has not decreased as fast over the past decade (Lung
Cancer Alliance, 2012). The 2013 Cancer Facts and Figures statistics show that the lung
cancer death rate for African Americans has declined faster than Caucasians (2.4% vs.
1.9%) due to more African Americans quitting smoking, but there still remain differences
in lung cancer mortality between African American, Hispanic, and Caucasian populations
(ACS, 2013). The differences in lung cancer mortality between Caucasians and African
Americans are the result of a number of factors, including differences in access to care,
quality of care, bias in treatment, stereotyping, and socioeconomic status (SES; Clark,
2009). Lower SES is frequently associated with lower health literacy and the ability to
understand healthcare information (ASCO, 2014). In fact, an analysis of the data reveals
that racial disparity has not decreased in the10 years from 1992 to 2002 (Gross, Smith,
Wolf, & Andersen, 2008). This fact has been confirmed by other studies (Kaiser Family
Foundation, 2012).
Much of the research contributing to the understanding and elimination of
disparities has focused primarily on the best-known factors associated with the
determinants of health such as race/ethnicity and SES (Berkowitz & McCubbin, 2005).
Healthcare disparities related to societal marginalization, patient distrust of the medical
community, and institutional discrimination are known to be present (Anderson, 2014).
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Patients who are marginalized have been shown to experience delays in the diagnosis and
treatment of their cancer and are less likely to receive recommended treatment options
leading to decreased survival (Anderson, 2014). Additional research in these areas of
health care processes and quality of treatment and care may contribute to our
understanding and help eliminate the disparities experienced by many racial/ethnic
minorities (Gross et al., 2008). The Institute of Medicine (IOM) highlighted the need to
avoid ineffective care and to increase the use of practices with proven evidence
(Smedley, 2003). In an effort to reach the IOM goal, President Clinton initiated the
Racial and Ethnic Health Disparities Initiative and set the goal of eliminating racial
disparities by 2010 (Health and Human Services, 1998). Because the United States did
not meet the goal of eliminating the multifaceted problem of health care disparity by
2010, solving this problem remains a focus for the United States. While the United
States is known to have one of the best health systems, evidence shows there is
inconsistent care given to cancer patients and that African Americans are less likely than
Caucasians to receive stage appropriate treatment for lung cancer (American Society of
Clinical Oncology (ASCO), 2013; Betancourt & Renfrew, 2011; IOM, 2013; Shugarman
et al., 2009).
One strategy to aid in reducing the disparities in cancer treatment between
racial/ethnic groups is to use evidence-based clinical practice guidelines that are disease
specific. The National Comprehensive Cancer Network (NCCN) clinical practice
guidelines are the most widely accepted and used cancer guidelines and have been shown
to improve the quality of care in cancer patients by providing the physician with the best
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clinical evidence available from randomized clinical trials for treating a cancer (ASCO,
2013; NCCN, 2014; Smith, 2000). The NCCN clinical practice guidelines were
developed by experts from a number of major cancer centers in the United States using
an unbiased process for evaluating clinical trial data and the clinical research literature in
an effort to aid in the treatment decision-making process. The NCCN clinical practice
guidelines are classified into categories (Category 1, 2a, 2b, and 3) by the strength and
consistency of the evidence and the consensus panel agreement to the recommended
guidelines. Clinical practice guidelines and standards of care change over time
depending on the data released from clinical trials. The current recommended guideline
for stage IIIB non-small cell lung cancer (NSCLC) is concurrent chemoradiation and for
first-line stage IV NSCLC is a two-drug combination of a platinum drug (either
carboplatin or cisplatin) plus another drug such as docetaxel, gemcitabine, pemetrexed,
paclitaxel, or vinorelbine. The addition of a biologic drug such as bevacizumab is
indicated for patients with nonsquamous NSCLC. Following the recommended clinical
practice guidelines provides the scientific basis for medical treatments, providing for
consistent practices among physicians, increasing quality care while allowing for fewer
treatment differences between patients, increasing efficiency, and lower costs. Overall,
the guidelines provide a roadmap for treatment but are not mandatory as physicians are
able to make certain clinical decisions based on each patient’s overall medical condition.
As the cost of the new therapeutic agents adds to the overall cost of treatment, it is key
that the clinical practice guidelines are incorporated into treatment decisions because
clinical practice guidelines are used for reimbursement by payers and for advocating for
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policies to ensure access to cancer care. The relationship between the provider and the
patient may also be improved if there is a discussion about clinical practice guidelines
and involving the patient in their own care allowing for improved treatment compliance.
The NCCN clinical practice guidelines are available for 97% of cancers and can be
applied to approximately 97% of the population in the U.S. (NCCN, 2014). However,
having clinical practice guidelines available does not ensure that they will be used
because the guidelines are not mandatory (Mok, 2014).
The goal for this research was to retrospectively evaluate the specific cancer
treatment of elderly African Americans, Caucasians, and Hispanics with advanced stage
IIIB or stage IV metastatic NSCLC using a national database from the NCI to evaluate
treatment according to the NCCN clinical practice guidelines. The results from lung
cancer research and health outcomes research in the early stages of NSCLC demonstrated
differences in the rate of surgery in African Americans and Caucasians. However, there
is limited research on lung cancer treatment in Hispanics, as well as on lung cancer
treatment patterns in the advanced stage of the disease comparing Caucasians, African
Americans, and Hispanics (Shavers & Brown, 2002). There is also little to no data on the
use and effect of clinical practice guidelines in lung cancer across racial/ethnic groups.
Therefore, the focus of this study was to evaluate the treatment of elderly Hispanic
patients diagnosed with advanced/metastatic NSCLC compared to African Americans
and Caucasians and the use of lung cancer clinical practice guidelines in the treatment of
NSCLC.
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This study contributed to the body of research in lung cancer disparity as it related
to the treatment of different ethnic groups according to the recommended treatment
guidelines established by NCCN. If patients are not treated according to the
recommended lung cancer guidelines for stage of disease, treatment differences may be
exaggerated. While it was difficult to determine the reason treatment was not provided
according to the clinical treatment guidelines, this research provided an understanding of
the treatment in NSCLC in African Americans, Hispanics, and Caucasians and provided
insight into whether physicians may be contributing to disparities by potentially not
following the clinical practice guidelines. Having an understanding of cancer treatment
patterns between racial/ethnic groups may allow the healthcare community to better
understand the potential causes for the disparities and identify strategies for eliminating
the disparity. Social change can be achieved through improving the understanding of
racial disparities, increasing awareness, and educating healthcare providers around
racial/ethnic differences and cultural sensitivity toward these groups.
This chapter provides the background on health disparity in lung cancer between
African Americans, Hispanics, and Caucasians with regards to the first line treatment of
advanced NSCLC. I will introduce the problem statement, the purpose of the study with
research questions and hypotheses, definitions of terms, and the limitations to a
retrospective study using a large population database. Clinical practice guidelines
provide healthcare providers with a resource for more consistent treatment across
racial/ethnic groups and ensure that the most current research discoveries are
incorporated into patient treatments. However, there tends to be variation in the use of
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these guidelines across disease entities. Therefore this study helped determine the extent
to which clinical practice guidelines were used in the first line treatment of
advanced/metastatic NSCLC in the elderly and address the needs for additional research.
Background
Lung cancer is a devastating disease and its incidence is expected to increase
worldwide over the next decade (ACS, 2014). Currently there are 1.6 million deaths
annually worldwide due to lung cancer and the WHO predicts a 70% increase in cancer
by 2030 (WHO, 2014). Eighty percent of lung cancers are diagnosed in current and
former smokers, in addition to individuals exposed to second hand smoke and
environmental pollutants, which also increase the risk of developing lung cancer.
Smoking is the leading cause of preventable cancer mortality in the United States and
worldwide (CDC, 2008). Approximately 56% of lung cancers are diagnosed once they
have spread to other parts of the body (Lung Cancer Alliance, 2013). The overall 5-year
survival rate for lung cancer is approximately 16%, which is less than the 5-year survival
for the other major cancers in the United States, including breast, colon, or prostate
cancer (Lung Cancer Alliance, 2013; SEER, n.d.). With regards to lung cancer mortality
and general cancer mortality, lung cancer represents 27% of all cancer deaths in the
United States (SEER, n.d.). African Americans have the highest mortality rates from
cancer, including lung cancer. The cancer mortality rate for African American men
between 2003 and 2007 was 296/100,000 compared to 225/100,000 for Caucasians
(ASCO, 2013).
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Disparities in cancer mortality have been well documented in the medical and
public health literature. In 2002, the IOM published a report describing the disparities in
healthcare between racial/ethnical groups and outlined multiple factors that contributed to
the differences, including socioeconomic status, insurance status, access to healthcare, the
healthcare provider, and the healthcare system, among other factors. Even when
controlling for socioeconomic status, insurance status, and access to healthcare, the
research has shown that there has not been an improvement in cancer disparities;
however, there has been a slow improvement in the quality of care for some cancer
patients due to newer treatments (ASCO, 2013; Rust & Cooper, 2007). But the greatest
opportunity for improving disparities in healthcare exists in the healthcare system
(Kilbourne, Switzer, Hyman, Crowley-Matoka, & Fine, 2006). Multiple factors within
the healthcare system contribute to cancer disparity, including patient delays in obtaining
care, physician delay in treatment, patient-physician interaction, lack of minority patient
providers within the healthcare system, and the regulations, policies, and resources within
the hospital, academic center, or clinic organization (Smedley, 2003).
Since the publication of the IOM report on healthcare disparities, research has
been dedicated to determining the reasons for the differences in healthcare treatment and
outcomes. Several definitions of disparities are used in the literature. The IOM defined
disparities as “the difference in healthcare services received by different racial/ethnic
groups that is not due to clinical need/appropriateness or preference by the individual”
(Smedley et al., 2003. Freeman and Chu (2005) described the causes for disparities in
cancer care and outcomes as culture, poverty, and social injustice. Cultural barriers occur
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when there are certain beliefs about cancer and treatment and when there is a lack of
information and understanding about cancer. To overcome some of the barriers of
culture, poverty, and social injustice Freeman and Chu reference the use of patient
navigators. Freeman and Chu also found that the healthcare provider might be
contributing to the disparities between patients because, when healthcare providers treat
patients, there is an inconsistency between what the provider knows and what the
provider provides to the patient. Betancourt and Renfrew (2011) and Kilbourne et al.
(2006) found that poor communication between the patient and the healthcare provider,
stereotyping/bias, the clinical decision process, and patient mistrust were causes for the
differences in healthcare. By applying equal treatment to all patients treatment
inequalities can be reduced.
One hypothesis for the causes of the disparities between racial/ethnic groups
comes from the social cognitive theory (SCT). The SCT has been used to understand
physician actions, physician attitudes, and unconscious thinking process. Research has
found that stereotyping by healthcare providers contributed to the differences in treatment
between racial/ethnic groups (Burgess, 2010; Burgess et al., 2004). Physicians are taught
to eliminate their personal judgment about patients; however, research has found that
physicians unconsciously assign patients to a category, which influences treatment
decisions, leading to differences in treatment patterns (Burgess et al., 2004; Kilbourne et
al., 2006).
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Problem Statement
The incidence and burden of lung cancer varies considerably according to the
demographic characteristics of patients, especially age, gender, and race/ethnicity. While
Hispanic men and women have one of the lowest incidences of lung cancer, African
American men have the highest incidence of lung cancer with 95.8 cases per 100,000
persons per year, compared to Caucasian men (74.5 cases/100,000 persons per year) and
Hispanic men (40.6 cases/100,000 persons per year; ACS, 2012; SEER, n.d.). Hispanic
women have the lowest incidence of lung cancer with 26.3 cases per 100,000 persons per
year as compared to African American women 38.0/100,000 and Caucasian women
40.0/100,000 (ACS, 2013; SEER, n.d.). Overall, five-year survival rates for African
Americans are also lower than those observed in Caucasians or Hispanics, 12.4% as
compared to 15.9% for Caucasian and 14.4% for Hispanics (ACS, 2012; ALA, 2010).
Despite low incidence rates, lung cancer is the leading cause of death among Hispanic
men and the second leading cause of cancer death among Hispanic women (ACS, 2012).
While there have been advances in the treatment of lung cancer and a decrease in the
incidence and mortality rates, the decreased rates have not been seen across all
races/ethnicities with African Americans still having a disproportionate burden of cancer
in the United States (Betancourt & Renfrow, 2011; Freeman & Chu, 2005; National
Cancer Institute, 2008; Office of Minority Health, 2013). Patients with metastatic stage
IV NSCLC that has spread outside of the lungs are usually treated with chemotherapy to
control their disease (NCI, 2013; NCCN, 2014). The treatment of lung cancer in the
context of the clinical trial setting is well documented in the literature; however, there are
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few data on how patients with advanced stage IIIB/metastatic stage IV lung cancer are
treated in the real world outside of the clinical trial setting (Reilly & Evans, 2006). While
the NCCN clinical practice guidelines for NSCLC have been in place since 1996 (NCCN,
2014), it is not known if the treatment outside of a clinical trial in the advanced/metastatic
first-line setting is equal across all demographic and clinical subgroups with similar stage
of NSCLC or to what extent the NCCN lung cancer clinical practice guidelines are
applied across different groups of patients.
In the clinical trial setting, patient inclusion/exclusion are generally well defined
and well controlled for comorbidities and concomitant medications; however, these
variables are not well controlled in the real world, which illustrates the difference
between treatment in a clinical trial and real world treatment. It remains unclear if
treatment and outcome disparities are due to the individual patient or to institutional
factors. Therefore, the purpose of this study will be to fill this gap in the literature and
evaluate how advanced stage NSCLC treatments compare across racial/ethnic groups
(i.e., African Americans, Hispanics, and Caucasians) as stratified by stage of disease and
histology according to the NCCN clinical practice guidelines while controlling for age
and gender.
In this study, I evaluated the relationship between first-line treatment for
advanced/metastatic NSCLC between African American, Hispanic, and Caucasian
individuals age 65 years and older and patients characteristics such as age, gender, stage,
and histology according to clinical practice guidelines. As the Hispanic population in the
United States increases, their inclusion in research efforts becomes more important. I
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evaluated lung cancer treatment according to established guidelines by race/ethnicity,
stage of disease, histology, geographic location, and age in order to determine potential
variation in treatment and identify ways to improve treatment outcomes. The implication
for positive social change from this research included an improved understanding of the
treatment trends for first-line metastatic NSCLC, particularly in Hispanics, and a better
understanding of the population at the highest risk of lung cancer mortality. This
understanding has implications for changing public policy and insurance reimbursement.
This study was important to conduct, as it is well known that disparities in the early
treatment of NSCLC exist; however, there are limited real-world data available regarding
the treatment patterns. There is also limited real-word data across race/ethnicity regarding
the treatment of patients in the later stages of lung cancer.
Purpose of the Study
The purpose of this retrospective quantitative research study was to determine the
relationship among Caucasian, African American, and Hispanic race/ethnicity, as
stratified by histology (squamous vs. adenocarcinoma), and stage of disease (IIIB or IV)
to the receipt of first-line treatment for NSCLC. Within each of the four strata (stage IIIB
disease adenocarcinoma or squamous cell carcinoma and stage IV disease
adenocarcinoma or squamous cell carcinoma), I controlled for age and gender. Treatment
according to the clinical practice guidelines was defined as the use of a recommended
chemotherapy, radiation therapy, biologic agent, or combination of these therapies
appropriate for the stage of disease and histology.
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Research Questions and Hypotheses
To better understand the treatment patterns of elderly African Americans and
Hispanic patients relative to Caucasians with NSCLC, I explored the following research
question and tested hypotheses to address the questions across the three ethnic groups.
Each of the following hypotheses was tested within the respective stage and histology,
creating a total of four strata. The four strata were (a) stage IIIB adenocarcinoma; (b)
stage IIIB squamous cell carcinoma; (c) stage IV adenocarcinoma; (d) stage IV squamous
cell carcinoma.
Research Question: What is the likelihood of Caucasian, African American, and
Hispanic patients with NCSLC being equally treated according to the NCCN clinical
practice guidelines within stage and histology strata after controlling for age and gender?
Null Hypothesis (H0): Caucasian and African American patients with NSCLC are
equally likely to be treated according to the NCCN clinical practice guidelines within
stage and histology strata, after controlling for age and gender.
Alternative Hypothesis (H1): Caucasian and African American patients with
NSCLC are not equally likely to be treated according to the NCCN clinical practice
guidelines within stage and histology strata after controlling for age and gender.
2. What is the likelihood of Caucasian and Hispanic patients with NSCLC being
equally treated according to the NCCN practice guidelines within stage and histology
strata after controlling for age and gender?
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Null Hypothesis (H2o): Caucasian and Hispanic patients with NSCLC are equally
likely to be treated according to the NCCN practice guidelines within stage and histology
strata after controlling for age and gender.
Alternative Hypothesis (H21): Caucasian and Hispanic patients with NSCLC are
not equally likely to be treated according to the NCCN practice guidelines within stage
and histology strata after controlling for age and gender.
3. What is the likelihood of Hispanic and African American patients with
NSCLC being equally treated according to the NCCN practice guidelines within stage
and histology strata after controlling for age and gender?
Null Hypothesis (H3o): Hispanic and African American patients with NSCLC are
equally likely to be treated according to the NCCN practice guidelines within stage and
histology strata after controlling for age and gender.
Alternative Hypothesis (H31): Hispanic and African American patients with
NSCLC are not equally likely to be treated according to the NCCN practice guidelines
within stage and histology strata after controlling for age and gender.
Theoretical Framework
Many factors influence racial/ethnic disparities, and as such, researchers have
used numerous theories to evaluate the differences, with no one overarching theory being
used to describe the healthcare differences seen among different groups. The theory that
served as the foundation for this study in the use of clinical practice guidelines in NSCLC
between racial/ethnic groups was the SCT by Bandera. SCT posits that one’s behavior is
based on environmental factors such as educational training, colleagues, family and
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friends, and observation, as well as personal factors such as cognitive and emotional
factors that all interact with each other (Burgess et al., 2004). SCT has two components
based on past experiences, one is cognition, and the other is motivation. These
components have been used in previous cancer research to evaluate how individuals
acquire their learning and how one’s past learning and past behaviors influence treatment
patterns. SCT has been used to determine an individual’s self-efficacy in treating
individuals of difference racial/ethnic backgrounds (Burgess et al., 2004).
SCT has been used to consider one’s thought processes, one’s judgment, and
one’s social influences in understanding racial/ethnic interactions in healthcare decisions.
If a healthcare provider believes that a patient or caregiver is less likely to adhere to a
recommended treatment or lacks support from family or friends, the healthcare provider
may not prescribe the therapy but instead prescribe a more appropriate therapy (van Ryn
& Fu, 2003). Burgess et al. (2010) state that, when physicians interact with racial/ethnic
minorities, the physician may experience anxiety, which in turn affects their ability to
make treatment decisions. There is also some evidence to suggest that the health system
contributes to disparity and that interventions to eliminate disparities can be improved by
providing treatment decisions that are less demanding and less mentally intense (van Ryn
& Fu, 2003). The factors that contribute to healthcare disparity include the patient, the
physician, the patient-physician interaction, third party payers, referral patterns of
physicians, and the guidelines within the hospital, academic center, or clinic organization
(Kilbourne et al., 2006, Figure 1). Institutional clinical practice guidelines may or may
not be in place that physicians follow when treating their patients (Yorio, Yan, Xie, &
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Gerber, 2012). Clinical treatment guidelines provide the physician with the tools to treat
cancer patients equally according to the best available evidence-based research and make
decisions that are less demanding and intense, thereby helping to eliminate treatment
disparity.

Figure 1. A Conceptual Framework Describing Healthcare Disparities. From
“Advancing health disparities research within the health care system: A conceptual
framework,” by A. M. Kilbourne et al., 2006, American Journal of Public Health, 96, p.
2116. Reprinted with Permission.
Nature of the Study
This study was a retrospective quantitative analysis of the treatment of elderly
African Americans, Hispanics, and Caucasians with advanced stage IIIB and metastatic
stage IV NSCLC using a secondary data source from the NCI (described below). In this
study, I tested whether there are differences in the chemotherapy, radiation therapy, or
biologic therapy administered in the first line treatment of African American and
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Hispanic patients with NSCLC as compared to Caucasians. All patients had stage
IIIB/IV NSCLC and comparable stage of disease. I identified and stratified patients by
stage (IIIB or IV) and lung cancer histology (squamous or nonsquamous histology). Age
and gender were controlled for using multivariable analyses. The criterion variable was
cancer treatment according to the NCCN clinical practice guidelines and the predictor
variables were age, gender, and race/ethnicity (African American, Hispanic, or
Caucasian). Analyses were performed within stage and histology strata given the
differences in treatment guidelines across these groups. All patients were Medicare
recipients and had comparable insurance coverage. The study was based on practice
guidelines for advanced/metastatic NSCLC using the 2008 NCCN practice guidelines for
patients diagnosed with NSCLC between 1998 and 2008 and the 2010 practice guidelines
for patients diagnosed from 2008 and 2010. The outcomes were reported as whether the
treatment given followed the recommended NCCN clinical practice guidelines according
to stage and histology.
Data Source
The NCI initiated the SEER program in 1972. SEER collects data from
population-based cancer registries in the United States based on cancer incidence and
prevalence, geographic location, cancer survival rates, and cancer mortality rates
representing 28% of the U.S. population from 18 U.S. cancer registries (SEER, 2013c;
Warren et al., 2002). The SEER database contains 250,045 patients with lung cancer
diagnosed from 1991 to 2009 (SEER, n.d.). In 1991, the NCI and the Centers for
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Medicare and Medicaid Services (CMS) began linking the SEER registry data with
Medicare claims data.
The lung cancer patients for this study were abstracted from the NCI SEER linked
Medicare database and included cancer cases reported in SEER from 1998-2011 and
Medicare claims from 1991-2010. I selected the SEER database because it is the
standard cancer research tool for healthcare researchers who are studying health patterns
and outcomes (Abel, 2011; NCI, 2013). Furthermore, the SEER database contains a high
racial/ethnic mix and the database population has a similar education and socioeconomic
mix to the general population (Abel, 2011). SEER data are available on age, gender,
ethnicity, and year of cancer diagnosis for 26% of African Americans, 38% of Hispanics
and 25% Caucasians (SEER, 2013c). Hispanic ethnicity in SEER is determined through
a Hispanic surname algorithm from the North American Association of Central Cancer
Registries Hispanic Identification Algorithm that was developed for enhanced sensitivity
compared to what was recorded in the Medicare database (SEER, n. d.). The Medicare
database contains claims information on healthcare procedures and utilization in
individuals 65 years of age and older with data available for the years 1991-2010. The
SEER and Medicare linked databases were used to identify specific chemotherapy agents
to treat lung cancer and to identify patterns of lung cancer care according to clinical
practice guidelines. Additional focus was on newer agents approved from 1998-2010 as
these drugs are widely used by oncologists and are part of the standard of care for treating
NSCLC. Claims data were evaluated starting in 1998, when several chemotherapeutic
agents were approved for lung cancer. The Food and Drug Administration (FDA)
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approved paclitaxel (Taxol) for use in NSCLC in 1998 and docetaxel (Taxotere) was
approved in 1999 for NSCLC as a single agent. The FDA approved pemetrexed (Alimta)
for NSCLC in 2004 and bevacizumab (Avastin) was FDA approved in 2006 for
unresectable adenocarcinoma NSCLC. Erlotinib (Tarceva), an oral chemotherapeutic
agent was FDA approved for the first-line treatment of advanced or metastatic NSCLC in
2013. Only chemotherapy administered claims data were evaluated to determine how
these new biologic/targeted agents were used in elderly Caucasians, African Americans,
and Hispanics diagnosed with NSCLC.
Definition of Terms
An understanding of the terms and acronyms used throughout the lung cancer and
disparities literature are important for understanding this research. Following are the
definitions of the acronyms and terms used in this research.
African American: An individual who is descended from any of the Black
populations in Africa. Also includes individuals from Haiti and Jamaica (U.S. Census
Bureau, 2010).
Caucasian: An individual of White race and has European, Middle Eastern or
North African origins (U.S. Census Bureau, 2010).
Clinical practice guidelines: Treatment recommendations based on a methodical
review of clinical evidence to optimize patient care (Institute of Medicine, 2011).
Disparity: Increase in the incidence, prevalence, burden of disease, and death
from disease in a population as compared to the general population (NCI, 2013).
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First-line therapy: The first treatment recommended for a disease and is usually
the standard treatment based on clinical guidelines (NCI, n.d.).
Hispanic: A person of Mexican, Puerto Rican, Cuban, Central, or South
American, or other Spanish culture (U.S. Census Bureau, 2010).
Metastatic: Cancer that has spread to another part of the body, outside of its
original site (NCI, 2013).
National Comprehensive Cancer Network (NCCN): A group of 23 cancer centers
in the United States that develop clinical practice guidelines that will improve the quality
and effectiveness of cancer care for patients (NCCN, 2014).
Non-small cell lung cancer (NSCLC): Type of cancer that originates in the
bronchus of the lung and is defined by the appearance of the cells (ACS, 2014).
Overall survival rate: The percentage of people who are still alive after they are
diagnosed with cancer or started treatment for a disease (NCI, n. d.).
Randomized clinical trial: A study in which the participants are assigned by
chance to separate groups that compare different treatments. Neither the researchers nor
the participants can choose the group (American Association for Cancer Research
[AACR], 2011).
Stage of disease: The amount of cancer and whether the cancer has spread from
the original site of diagnosis to another part of the body. The stages of cancer differ for
each cancer type and with the staging system (AACR, 2011).
Standard of care: The currently accepted and widely used treatment for a
particular cancer based on previous clinical research (AACR, 2011).
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Social cognitive theory (SCT): A model that states individuals learn and gain
knowledge based on experience, motivation, observing others, and interactions with
others (Pajares, 2002).
Self-efficacy: An individual’s capability to succeed in a particular situation
(Bandura, 1977).
Targeted agents: A treatment using drugs or other agents that attack specific
cancer cells while limiting the effect on normal cells (AACR, 2011).
Tumor board: A group of physicians and healthcare providers from different
cancer specialties who discuss a patient medical case and options for treatment (Scher,
2012).
Assumptions
One of several assumptions made for this study was that the study data were
representative of the lung cancer population in the United States over 65 years of age. It
was also assumed that differences in treatment outcomes would be due to noncancer
health and co-morbidities. It was further assumed that the stage of lung cancer and
histology would be sufficient to determine appropriate lung cancer care. It was also
assumed the data from the SEER-Medicare database were complete and accurate, and
that racial/ethnic classifications were accurate.
Scope and Delimitations
The strengths of this study are that this is a large retrospective population-based
study using the SEER database that collects data representing 28% of the U.S.
population. The combined SEER database and the Medicare database provided for a
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more complete analysis of the data and allowed for identifying chemotherapy treatments
as compared to using the SEER database alone. SEER collects data from hospitals,
physician offices, clinics, nursing homes, and radiation facilities and is able to capture
approximately 99% of all cancers (NCI, 2012).
This was a retrospective study and was limited as to why a specific treatment was
not given. It would be difficult to determine whether the treatment was not given because
of patient refusal, whether the physician did not offer the treatment, or because comorbid
conditions existed. Because the population studied was aged 65 years and older with
Medicare the results cannot be generalized to the general population. The use of a
Medicare database limits this research to only patients with Medicare Part A and Part B
and results from this study may not apply to commercially insured patients or patients
treated in a Veterans Affairs facility. Also, because this study was an evaluation of
patients with advanced/metastatic NSCLC, the results cannot be generalized to patients
with earlier stage disease. The SEER-Medicare database does not contain data on the
patient performance status, one of the indicators oncologists use when making treatment
decisions. SEER represents approximately 28% of the U.S. population; therefore, local
treatment differences may not be reflected in this study. Another limitation may be the
misclassification of a patient’s ethnicity, particularly Hispanic ethnicity, in cancer
registries and in the SEER database. Accounting for missing variables is a limitation to
conducting a retrospective study. Dummy variables were used to help control bias.
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Inclusion/Exclusion Criteria
Participation was delimited to patients with a diagnosis of advanced stage IIIB or
stage IV metastatic NSCLC who are Caucasian, Hispanic, or African American; are age
65 or older; and are enrolled in Medicare Part A and Medicare part B insurance upon
being diagnosed with NSCLC. The Medicare database does not include patients with
Medicare insurance Part C (HMO/PPO); therefore, these patients were not included in the
study. As well, patients who may have been diagnosed with another cancer prior to lung
cancer, except non-melanoma skin cancer were excluded from this study. Patients with
stage I-IIIA NSCLC at diagnosis and patients with histology other than adenocarcinoma
or squamous cell carcinoma were also excluded from study because disparities in patients
with early stage disease had been fairly well studied.
Significance of the Study
Previous research has shown that when patients have similar insurance status,
there are differences in care received between racial/ethnic individuals. Clinical practice
guidelines in oncology have been developed for most all tumor types and are available to
all healthcare professionals. Following clinical practice guidelines allows for more
consistent patient care with less risk of inappropriate care and increased costs (Field &
Lohr, 1992). This study helps advance the knowledge of cancer disparities by focusing
on the healthcare system as a factor contributing to the gap in cancer care. While it is
well known that differences in the receipt of health care exist among minority groups due
to lack of insurance or access to care, this research was focused on understanding other
factors that contribute to the gap in health care and outcomes by evaluating the use of
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clinical practice guidelines in patients with advanced/metastatic NSCLC with similar
insurance status. By focusing on factors contributing to the gaps in patient care from the
health system, additional insight may be gained to explain the disparities seen and
provide the potential for additional prospective research evaluating the health care system
as a factor contributing to differences in cancer care.
Summary
There are challenges to reducing the gaps in health care and outcomes among
racial/ethnic groups. Eliminating these disparities is a goal of most public health
professionals and is also one of the goals for Healthy People 2020 (Healthy People,
2010).
Much of the research in health disparities has focused on social determinant
factors with less emphasis on the health care system as a contributor to the disparities in
care. Even when SES, insurance status, access to care, and stage of disease are equal,
gaps in the health outcomes remain. Racial/ethnic minorities receive lower quality care
and have lower health outcomes. Research from Burgess (2002, 2010) and van Ryn
(2002) suggested that physician behaviors and bias may contribute to disparities.
Researchers have also documented discordant relationships between physicians and
patients. Physicians’ unconscious stereotypes and biases may be affecting self-efficacy,
communication with patients, and adherence to recommended practice guidelines
(Burgess et al., 2010). Improving quality of care may improve the communication
between the patient and physician and facilitate a mutually shared treatment decisionmaking process, where the physician is not solely held responsible for the treatment
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decisions. Improving patient care through evidence-based medicine and reducing costs
with greater efficiency may be possible. Clinical practice guidelines provide evidencebased recommendations appropriate for stage of disease and can potentially increase
physician self-efficacy when interacting with racial/ethnic minorities.
In Chapter 2, I will outline the study framework described in Chapter 1 in further
detail by providing a thorough review of literature on relevant concepts and theories and
literature related to the research questions, hypotheses, the problem statement, and the
study objective. In addition, I will provide a historical perspective of lung cancer
treatment in Chapter 2. Chapter 3 will include a description of the nature and design of
the study, the patient population with justification for the sample size, the research
methodology, and the research techniques relevant to data collection and analysis.
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Chapter 2: Literature Review
Introduction
Lung cancer is a major health problem in the United States. In 2012, there were
approximately 226, 000 new cases of lung cancer diagnosed with approximately 112,000
deaths due to the disease (NCCN, 2014). African Americans have the highest incidence
rate of lung cancer at 75/100,000 as compared to Caucasians at 64/100,000, and
Hispanics have the lowest incidence of lung cancer at 32/100,000 (ALA, 2010). There
are numerous studies to confirm the association between cigarette smoking and lung
cancer with the majority of lung cancers that develop in smokers being preventable.
Lung cancer is usually diagnosed in the sixth or seventh decade of life and in the
advanced stage of disease when the prognosis is poor and when the disease is rarely
curable (ALA, 2010). NSCLC and small cell lung cancer (SCLC) represent the two
major types of lung cancer with non-small cell lung cancer representing 85% of all lung
cancer cases (ALA, 2010). Overall, most minorities have higher incidence rates, higher
mortality rates, and lower 5-year survival rates after being diagnosed with cancer as
compared to Caucasians (ACS, 2013; ASCO, 2013). Despite treatment with
chemotherapy, radiation, and newer targeted agents, lung cancer still has a higher
mortality rate as compared to other cancers (ALA, 2013). According to the ACS (2009),
as the technologies and therapies to treat cancer improves, racial/ethnic disparities may
also increase.
Major advances in the treatment of lung cancer have occurred in the past 30 years,
yet not all individuals share equally in receiving cancer care (Freeman & Chu, 2005;
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Lillie-Blanton et al., 2008). Cancer care is complex. There are multiple factors that
directly impact the patient and that contribute to the disparities in cancer care seen
between African Americans, Hispanics, and Caucasians. These factors include lack of
education, lack of access to care, environmental factors, racism, the type of health
insurance, and the overall healthcare system (Betancourt et al., 2011). Differences in
referral patterns to a cancer specialist and differences in the level of insurance coverage
may determine the type of treatment given. Patients with a lower level of benefit may not
receive the same treatment as a patient with a higher level of the same insurance benefit
(Slatore, Au, & Gould, 2010). These differences may also be due to the type of facility
where treatment is received and constraints within the healthcare facility such as
reimbursement and available resources (Kilbourne et al., 2006). The IOM published a
landmark paper entitled “Unequal Treatment: Confronting Racial and Ethnic disparities
in Healthcare” that reported on the disparities seen in healthcare and on the factors that
contributed to the disparities (Smedley et al., 2003). Minorities tended to receive poorer
quality of care than nonminorities even when there was equal insurance and income level
(American College of Physicians, 2010; Betancourt & Renfrew, 2011; Clark, 2009;
Smedley et al., 2003). Factors contributing to the disparities included poor
communication between the patient and the healthcare provider, stereotyping/bias by the
healthcare provider, and historic treatment practices that may have caused African
American patients to mistrust the healthcare provider and the healthcare system
(Betancourt & Renfrew, 2011; Meyers, 2007; Smedley et al., 2003). Differences in care
were noted between teaching and nonteaching hospitals, referrals to specialty physicians,
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and the availability of translators to aid in communicating with the healthcare provider.
Data from the literature also show that other factors contributing to the increased
mortality and disparities in lung cancer are stage of disease at diagnosis and the effective
treatment of the disease (Li et al., 2011). In addition, the IOM noted that healthcare
providers might contribute to the differences in care through their own beliefs about race
and subconsciously decide how to treat the patient (Smedley et al., 2003). In a follow-up
report, Clark (2009) noted that little to no progress was made in providing access and
quality care toward eliminating healthcare disparities since the 2003 IOM report. These
themes from the IOM paper have been documented over the years. Forty years after the
first healthcare disparities paper was published, suboptimal cancer treatment for many
patients still exists (Lillie-Blanton et al., 2008).
In an effort to reduce the lung cancer death rate and improve the treatment of
cancer patients, Healthy People 2020, a national initiative from the U.S. Department of
Health and Human Services, set the cancer goals of reducing the overall cancer death rate
and reducing the lung cancer death rate in individuals by 2020 (Healthy People 2020,
2013). However, if healthcare disparities are to be eliminated, the cause of the disparities
must be understood. Therefore, the purpose of this study was to conduct a retrospective
evaluation of patients with advanced NSCLC to determine if treatment differences exist
in the first-line setting of NSCSL between Caucasians, Hispanics, and African
Americans.
In this chapter, I outlined the current treatment standards for lung cancer, the
current status around the use of clinical treatment guidelines in lung cancer, and how the

29
guidelines currently affect outcomes. The theoretical foundations behind healthcare
disparities were described using the SCT and the cancer disparities model. This paper
contributes to the current body of literature in the area of healthcare disparities in African
Americans, Hispanics, and Caucasians.
Literature Search Strategy
The databases that I accessed to search for information on treatment guidelines in
lung cancer in racial/ethnic minorities included PubMed, OVID, Medline, Scopus, and
Google Scholar. The terms I used to search for the most current peer-reviewed articles
include NSCLC, non-small cell lung cancer, lung cancer, disparities, health care
disparities, practice guidelines, insurance, clinical treatment guidelines, Hispanic, race,
ethnicity, and quality of care. Articles were limited to studies in the United States,
published in English, with full-text available, that described racial/ethnic treatment
patterns and disparities in lung cancer. Articles were delimited to the years 2000 to 2013
in order to capture the most current treatment practices in lung cancer. I also researched
the reference lists of identified articles for additional relevant papers. Papers published
prior to 2000 were included in order to capture several landmark papers that initially
identified healthcare disparities in the United States and to capture background
information around the theoretical foundations of healthcare disparities. Articles
describing healthcare disparities in advanced lung cancer patients were limited as most
research describing disparities in NSCLC were conducted in early stage patients where
the comparisons were primarily between African Americans and Caucasians. Limited
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data were found describing healthcare disparities in Hispanics with lung cancer and
advanced disease.
Theoretical Foundation
The SCT by Bandura (1977) and the cancer disparities model by Freeman and
Chu (2005) serve as the framework for this investigation. The SCT originated from the
field of psychiatry to describe learning behaviors and was later expanded by Bandura to
include human behavior (Pajares, 2007). The SCT describes the influence of three
factors on behavior: environmental, behavioral, and personal. The ability to change one’s
thoughts and behaviors are dependent upon one’s perceptions, goals, and willingness to
change (Smith, 2000). As such, the SCT has been applied to understand behaviors in
stressful situations, problem-solving situations, and outcomes and expectations (Pajares,
2002).
One of the key factors of the SCT is self-efficacy, which was first introduced by
Bandura (2005) (1977). Self-efficacy provides for the modeling of behaviors and is
obtained by observing the actions of others and from one’s own experiences (Pajares,
2002). According to the SCT, individuals have control over their thoughts while
behaviors are influenced by one’s beliefs and capabilities (Pajares, 2002). The use of
social cognitive models has shown that prejudice and stereotyping by healthcare
providers is a normal phenomenon. Individuals have the ability to control their actions,
beliefs, motivation, and control outcomes based on Bandura’s self-efficacy model. This
model can be applied to the confidence physicians have in their ability to treat different
racial/ethnic patients, follow clinical guidelines, and treat NSCLC (Burgess et al., 2007).

31
Physicians who do not have positive interactions with racial/ethnic minority patients or
are not confident in their ability to treat these patients may not communicate well with
them or feel comfortable treating them. This model can be applied to the confidence
physicians have in their ability to treat different racial/ethnic patients, follow clinical
guidelines, and treat NSCL. As well, the patient may sense that the physician is
uncomfortable and in turn may not trust the physicians’ judgment or follow the
recommended therapy (Dans et al., 2007). There is also evidence that individuals of
different races/ethnicities process information differently and this difference affects
behaviors and compliance to treatment (Van Ryn et al., 2003). Even if the guidelines
have the same effect in all races/ethnicities, physicians may make trade-offs when
assessing the risks and benefits of the guidelines (Dans et al., 2007). The physicians’
intention to use the guidelines and having the skills to treat the patient according to the
guidelines are factors that can influence the use of the clinical guidelines (Michie et al.,
2005). Physicians who do not believe in the clinical guidelines are less likely to follow
the recommended clinical guidelines. The use of clinical practice guidelines may also be
a barrier if the healthcare provider lacks self-efficacy.
Freeman and Chu’s (2005) disparity model describes three interrelated causes for
the disparities seen in cancer care: (a) low SES; (b) culture; and (c) social injustice.
Social injustice is defined as the bias associated with access to treatment, including
geographic access, and the perceptions one has of racial/ethnic groups (Freeman & Chu,
2005). Within each of the three causes there are barriers that need to be overcome by the
individual, by the healthcare provider, and by the healthcare system. While research has
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documented social determinants, insurance status, and access to care as contributors to
racial/ethnic disparities, even when these factors are absent differences in care exist
(Pienedo, 2011). The ability of the patient to navigate the healthcare system has been
shown to contribute to healthcare disparities (Freeman & Chu, 2005). The relationship
between the physician and the patient may be contributing to the disparities in care. The
effectiveness of communication, cultural awareness, and the patient’s level of trust in the
physician are factors for a strong physician-patient relationship and are factors that
contribute to the physicians’ treatment decisions. However, research shows African
American patients believe they have better relationships and treatment with their
physician if they are of the same race/ethnicity (Saha et al., 2003).
The conceptual framework for research gaps in the treatment of patients,
according to race/ethnicity, can be reflected in the quality of care delivered and outcomes
(Betancourt & Renfrew, 2011; Meyers, 2007). The difference in quality cancer care
ultimately affects the over or under utilization of resources and test, contributes to
medical errors, and potentially increased medical costs. While patient preferences may
explain some of the differences in care, it only contributes a small part to cancer
disparities. Since the behaviors associated with healthcare treatment and outcomes are
complex and involve multiple factors no one theory can be used to explain the treatment
differences or the disparities seen in the care between racial/ethnic groups (Dressler et al.,
2005; Meyers, 2007; Smith, 2000).
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Literature Review
Historical and Current Perspective
Over three decades ago the first paper that described the racial differences in
cancer survival and mortality was published. In this landmark paper entitled, “Alarming
Increase in the Cancer Mortality in the U.S. Black Population (1950-1967),” Henschke et
al (1973) described the differences in mortality rates between African Americans and
Caucasians for a variety of cancers. At the time, the biggest difference in the increased
cancer mortality rate in African Americans was from lung cancer and this difference was
thought to be due to environmental factors (Henschke et al, 1973). With the increased
number of African Americans who were being diagnosed with cancer and needing
medical care, there was a burden on the healthcare system (Henschke et al., 1973). This
increase in the diagnosis of cancer and increase in cancer mortality in African Americans
led to the initiation of cancer surveillance according to race and ethnicity that today now
includes Caucasians, African Americans, and Hispanics among other races/ethnicities in
the United States (Brawley, 2006). To assess if there are differences in treatment across
ethnicities/races this paper will determine how first line NSCLC treatments compare
across racial/ethnic groups, specifically African Americans, Hispanics, and Caucasians
and the likelihood of physicians treating according to the clinical practice guidelines.
Prior to 1993 minorities and women were not routinely included in clinical trials
and were therefore underrepresented in clinical research (Society for Women’s Health
Research, 2011). In 1987, the NIH developed a policy stating that minorities and women
should be included in clinical trials. To ensure that these two groups were included in the
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trials conducted through the NIH, the NIH Revitalization Act was passed in 1993 that
mandated minorities and women be included in clinical trials and also required that the
number of women enrolled in trials should be large enough to detect differences between
the genders (National Institutes of Health, 2001). In addition, gender and race were
required to be analyzed to determine if there were differences in treatment (U.S.
Department of Health and Human Services, 2005). However, years’ later women and
minorities are still underrepresented in most clinical trials (Intercultural Cancer Council,
2011).
Racial differences and health disparities between African Americans and
Caucasians have been well documented over the years (Brawley, 2006; Freeman & Chu,
2005; Lillie-Blanton et al., 2008; Shugarman et al., 2009; Smedley et al., 2003).
According to the NCI, African Americans have the highest cancer incidence and
mortality rates of any ethnic group (Howlander et al., 2013). In fact, African American
men have 1.4 times higher mortality rates from cancer as compared to Caucasian men
(Shavers & Brown, 2002; Ward et al., 2004). African Americans are also twice as likely
as Hispanics to die of cancer (Shavers & Brown, 2002). Based on these numbers,
African Americans have an overall reduced life expectancy as compared to Caucasians
and Hispanics. Research describing cancer disparities has been conducted comparing
African Americans to Caucasians with limited research evaluating disparities to other
racial/ethnic groups (Saeed, et al., 2012). Although cancer mortality has been decreasing
in African Americans, the decrease has not been as great for African Americans as for
Caucasians (Shavers & Brown, 2002). And while there is a vast amount of literature to
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document the existence of health disparities, there still has not been a significant
reduction in the disparities seen between the racial/ethnic groups, indicating that
additional research is needed in order to reach the goal of eliminating cancer disparities.
Cancer incidence rates and mortality rates in Hispanics have been tracked since
1992 (ACS, 2009). Hispanics tend to have a lower incidence of cancer overall as
compared to Caucasians, except for cervical and uterine cancer, liver cancer, and stomach
cancer (ACS, 2009); however, Hispanics have cancer mortality rates similar to
Caucasians for lung cancer (Shavers & Brown, 2002). While the trends in cancer
incidence and mortality in Hispanics have been followed for a much shorter period of
time, studies have documented that racial disparities in treatment exists, although
Hispanics are not studied as frequently as African Americans (Agency for Healthcare
Research and Quality, 2012; Saeed et al., 2012; Betancourt & Renfrew, 2011; Smedley et
al., 2003). Therefore, this paper evaluated how NSCLC treatment paradigms compare
across racial/ethnic groups including African Americans, Hispanics, and Caucasians and
if these groups differ in the treatment received for advanced stage IIIB or stage IV firstline metastatic NSCLC and if the patients are treated according to the current clinical
practice guidelines.
Non- Small Cell Lung Cancer and Treatment
NSCLC and small cell lung cancer (SCLC) are the two major types of lung
cancer. NSCLC is the more common and represents 85% of lung cancer cases and will
be the focus of this paper. There are several major cell histology that are used to describe
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NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma
representing 40%, 30%, and 15% of histology respectively (ACS, 2013).
Because there is not a routine screening test for lung cancer, approximately 75%
of patients are diagnosed in the advanced stages of the disease when the prognosis is poor
and is rarely curable (ALA, 2010; Hardy et al., 2009). The treatment of NSCLC depends
on the stage of the disease when diagnosed, on the patient’s performance status, and on a
number of other factors. Stage IV metastatic NSCLC is a cancer that has spread outside
of the lungs to other parts of the body making the disease incurable (ACS, 2013).
Patients with advanced stage metastatic NSCLC are usually treated with a platinumbased doublet; the only recommended exception is a triplet combination with platinum
based chemotherapy with bevacizumab for adenocarcinoma histology in appropriate
patients. The FDA approved agents for treating advanced stage NSCLC are cisplatin,
carboplatin, paclitaxel, docetaxel, gemcitabine, pemetrexed, erlotinib, and bevacizumab
(NCCN, 2013). Other drugs are available to treat NSCLC according to the National
Comprehensive Cancer Network guidelines, however they are not FDA approved.
Radiation therapy in combination with a platinum agent is recommended in stage IIIB
NSCLC. Radiation alone may also be administered to patients with metastatic disease as
palliation (NCCN, 2013). As targeted therapies are approved for NSCLC, the treatments
become more expensive and the treatment becomes more complex. As these newer and
more expensive therapies are incorporated into the clinical practice guidelines for use in a
broader patient population, do all patients receive these agents as recommended? This
study evaluated the real-world treatment of patients with advanced/metastatic NSCLC to
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determine if they were treated according to the recommended NCCN clinical practice
guidelines.
Clinical Practice Guidelines
The IOM defines clinical practice guidelines as “systematically developed
statements to assist practitioners and patient decisions about appropriate health care for
specific clinical circumstances (Smedley, et al, 2003).”
Clinical practice guidelines define the “gold standard” of treatment or best
practices and provide health care professionals with the tools to provide high quality care
based on the most current information and research from clinical trials. Clinical trials
provide the foundation for developing clinical practice guidelines in oncology; however,
there are few minorities that participate in clinical trials. Only 5% of African Americans
and 1% of Hispanics participate in clinical trials today (Coakley et al., 2012). Many
African Americans still recall the Tuskegee experiment from the 1970s and have distrust
for clinical trials (Gamble, 1997). Clinical practice guidelines are an important part of
cancer care as they can influence the physician’s decision for appropriate treatment and
care, provide the physician with evidence gained from clinical research to reduce
treatment variations between patients, potentially improve treatment outcomes, reduce
morbidity and mortality, and can improve the quality of care (Woolf, Grol, Hutchinson,
Eccles, & Grimshaw, 1999). Disparity develops when clinical practice guidelines are
followed for one patient population but not another population. Clinical research
conducted at Veteran Affairs hospitals demonstrated that when cancer patients are treated
with similar therapy the outcomes are similar across patients regardless of socioeconomic
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status (Shavers & Brown, 2002). However, there is disagreement with the finding from
the VA hospital findings as noted by Samuel, Landrum, McNeil, Bozeman, Williams,
and Keating (2014). Although patients may have the same clinical problem, patients may
or may not receive the same treatment depending upon the location of the facility where
the treatment is administered, the physician’s awareness of the clinical guidelines, and the
physician’s clinical experience (McKinlay, Link, Freund, Marceau et al., 2007; Samuel et
al., 2014). McKinley et al. (2007) also noted that race and socioeconomic status had no
effect on whether clinical practice guidelines were followed. According to the NCCN
guidelines, the current treatment for stage IV NSCLC is treatment with chemotherapy,
radiation therapy, or a targeted agent such as bevacizumab (NCCN, 2013). Treatment
will depend upon the histology of the tumor, the location of the tumor, the number of
metastases, and the patient’s overall medical condition (NCCN, 2013). While stage IV
lung cancer is not curable, treatment can improve the quality of life and extend survival
for some patients.
Clinical practice guidelines, when followed, have the potential to change
healthcare providers’ behaviors, to improve the quality of care patients receive, and
enhance the outcomes from treatment (Smith, 2000; Woolf et al., 1999). The adoption of
clinical practice guidelines tends to be dependent upon the quality and strength of the
research to support the guideline, upon the physician attitude and type of practice, and
upon the patient; however, an understanding of the influence of clinical practice
guidelines on healthcare differences and disparities in NSCLC is limited (Graham et al.,
2011; Visser, Ma, Zak, Poulsides, Norton, & Rhodes, 2012).
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Compliance to clinical practice guidelines varies (Hakkennes & Dodd, 2007).
Factors that influence clinical practice guideline adherence include physician age and
years of practice experience (McKinlay, 2007). Grol and Grimshaw (2003) and
Hakkennes and Dodd (2007) showed that up to 40% of patients are not treated according
to practice guidelines and receive unnecessary treatment. Foy et al. (2002) showed that
when clinical practice guidelines are implemented and used there was an increase in
physician compliance to following the guidelines. There is evidence to suggest that 57%
of patients with early stage NSCLC are treated with surgery then chemotherapy as
recommended by the guidelines (Cancer Quality Council, 2013). Bach (2005) suggests
that African Americans receive care at facilities of lower quality and as such clinical
practice guideline may not be followed. When practice guidelines were followed,
acceptance varied by the type of cancer (Harlan et al., 2005). Harlan et al. (2005), Woolf
et al. (1999), and McKinlay (2007) also suggest that following treatment guidelines can
be used as a benchmark to improve the quality of care for patients. Since clinical practice
guidelines in oncology are generally updated yearly or as needed, following clinical
guidelines provide healthcare providers with the ability to stay current with research
progress and could help bridge treatment gaps (Li et al., 2011). In addition, when
patients are aware of the clinical practice guidelines they have the ability to make more
informed decisions about their care and help improve quality of care. Providing
consistent care could reduce mortality and morbidity in cancer patients (Austin et al.,
2010; Evensen et al., 2010; Harlan et al, 2005; Li et al., 2011; Meyers, 2007).
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The Guidelines for NSCLC
Clinical practice guidelines are used in a variety of healthcare environments from
the physician, the nurse, to insurance payers for the objective of standardizing and
improving the quality of care. The guidelines provide the diagnosis, treatment, and
palliative care for a variety of cancers, including NSCLC. Clinical practice guidelines for
NSCLC provide healthcare providers with the currently accepted treatments for patients
based on the evidence from clinical trials. The recommended guidelines for advanced
stage IIIB or stage IV NSCLC were used as the basis for determining outcomes in this
study. The physicians’ treatment plan will depend upon the histology of the tumor, the
location of the tumor, the number of metastases, and the patient’s overall medical
condition (NCCN, 2013).
For stage IIIB NSCLC the recommended treatment is concurrent therapy of
combined platinum-based chemotherapy with once daily radiation in patients with
minimal weight loss (Jett et al, 2007). The effect of radiation or chemotherapy alone is
not as effective as the combination. Treatment should be administered as soon as
possible after diagnosis.
For stage IV NSCLC, the patient usually has metastatic disease. Approximately
one third of patients will be diagnosed with a single brain metastasis where surgery
followed by radiation to the brain is recommended (ACS, 2014). Stage IV disease is
present if there is the presence of a malignant pleural effusion. According to the NCCN
practice guidelines, the current treatment for stage IV NSCLC is chemotherapy, radiation,
or a targeted agent such as bevacizumab (NCCN, 2013). The guidelines recommend
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treatment for 4 to 6 cycles or until disease progression. The treatment of NSCLC
depends upon the patients’ performance status, which is a known prognostic factor for
improved survival (Azzoli, Giaccone, & Temin, 2010). While stage IV lung cancer it not
curable, treatment can improve the quality of life and extend survival for some patients.
Clinical Trials and Quality of Care
Clinical trials are the gold standard for providing evidence that defines the
standard of care in cancer. Oncology clinical practice guidelines are developed for use in
the decision- making process of patient care using the evidence based on the results of
large randomized controlled clinical trials and are used for improving the quality of
patient care. Accurate and timely reporting of clinical trial results is essential for
determining the validity and credibility of the data and for establishing and maintaining
quality care. However, there is evidence that the reporting of clinical trial results in
oncology is inadequate and inconsistent (Dancey, 2010; Schultz et al., 2010). The
Consolidated Standards of Reporting Trials (CONSORT) guidelines were established for
reporting the essential elements to include for all clinical trial reporting (Maher et al.,
2010). These elements include, for example, the name of the drug, the trial design
details, the administration of the drug, the dosing, adverse events, and supportive care
measures (Duff et al., 2010). Research revealed that 11% of oncology clinical trials
reported in top peer-reviewed journals included all the CONSORT elements for clinical
trial reporting and less than half of the articles reviewed contained data about dose
modifications for renal insufficiency or patient monitoring (Duff et al., 2010). However,
CONSORT does not include some of the complexities of administering chemotherapeutic

42
agents. Clinical practice guidelines do provide the clinician with the most current
oncology treatments and care and provide information for oncology drug reimbursement;
however, there needs to be transparency and consistency in reporting the results. The
ability to provide consistent treatment and quality care in patients may help reduce
disparities.
Disparities
A large amount of literature exists that reveals there are differences in healthcare
treatment and in outcomes between Caucasians and African Americans based on
socioeconomic status (SES). Even when SES is controlled, disparities in health status
still remain (Penner, 2007). While there are data available to describe the differences in
treatment and care for patients with cancer, the literature emphasizes the earlier stages of
lung cancer disparities primarily and in African Americans compared to Caucasians (Yin,
Morris, Allen, Cress, Bates, & Liu, 2010). There are limited data evaluating the
differences in healthcare among patients with advanced stage NSCLC and there is limited
data in patients who are Hispanic.
Potosky, Saxman, Wallace & Lynch (2004) evaluated the initial treatment of
approximately 900 NSCLC patients across all stages of disease and found that overall
52% of patients received the recommended treatment according to stage of disease as
determined by the ASCO practice guidelines. When treatment was stratified by
race/ethnicity, African Americans and Hispanics received recommended therapy less
frequently than Caucasians, 44%, 46%, and 53% respectively (Potosky et al., 2004).
When patients were evaluated by stage of disease alone, patients with stage IV advanced
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NSCLC received recommended initial treatment 41% of the time. Potosky and
colleagues suggested there might be gaps in quality of care for patients with NSCLC.
In another study Shugarman and colleagues (2009) utilized the SEER database to
evaluate treatment differences between race/ethnic groups with advanced NSCLC and
found that half of the time appropriate and timely treatment was not given to African
Americans with stage IV disease as compared to Caucasians (Shugarman et al. 2009).
There were also differences in the timeliness of receiving therapy between race and
gender and stage of disease at the time of diagnosis. Overall, patients with stage III
NSCLC were more likely to receive timely treatment (Shugarman et al., 2009).
Previous research suggests there may be differences in treatment outcomes
between patients. From 1974-2001, the Southwest Oncology Group evaluated over
19,400 cancer patients in 35 clinical trials, which included nearly 2700 patients with lung
cancer to determine if racial disparities existed in overall survival (Albain et al, 2009).
The study included an average of 11% African Americans. Because patients were
enrolled in clinical trials, there was consistency in the treatment received and in followup for all patients. While there were differences in overall survival reported between
African Americans and Caucasians for certain cancers, there was no statistical association
between race and overall survival for patients with NSCLC (Albain, et al, 2009). Factors
such as gender, age, weight loss, performance status at diagnosis, and stage of disease
have been found to be associated with outcomes in patients with NSCLC (Blackstock et
al., 2002). In a study conducted between 1989 to 1999 by the Cancer and Leukemia
Group B (CALGB) the effect of race/ethnicity on survival was retrospectively evaluated
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based on 5 phase II and phase III clinical trials from various cancers (Blackstock et al.,
2002). A total of 458 Caucasian and 46 African American patients with advanced stage
IIIB or IV NSCLC were evaluated for survival. Most patients completed a questionnaire
providing their educational level, income, medical insurance coverage, and employment
status prior to starting therapy. African American patients were more likely to be
unmarried, unemployed, lack insurance, and have a lower socioeconomic status, lower
performance status and weight loss at diagnosis. The results revealed that the estimated
one-year survival for Caucasians was 30% versus 22% for African Americans. When
adjustments were made for weight loss and performance status, African Americans had
greater weight loss than Caucasians, but this did not affect survival. These authors
concluded that while race/ethnicity did not affect survival, weight loss and performance
status prior to treatment had a greater impact on treat outcomes. In a Veterans Affairs
Cooperative Study, no statistical difference in response rate or performance status was
noted between African Americans and Caucasians with NSCLC treated with
chemotherapy (Shavers & Brown, 2002). Both African Americans and Caucasians
experienced a similar 5-year overall survival rate; however, African Americans were 30%
less likely to receive palliative care despite having equal insurance coverage (Shavers &
Brown, 2002). Advanced age has been found to be a predictor for physicians not using
the clinical practice guidelines to determine treatment (Wang et al., 2012).
Studies in early stage NSCLC evaluating disparities found that only patients with
stage I, II or III NSCLC received appropriate therapy for stage of disease and that
treatment was related to the age and race of the patient (Potosky et al., 2004). In a report
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by Bach and colleagues (2005b), African Americans with early stage NSCLC were less
likely to have curative surgery than Caucasian patients despite having similar insurance
and economic level. A study from the University of Texas confirmed the results from
Bach and others and found that African Americans received therapy according to clinical
practice guidelines for early stage cancer 37% less often than Caucasians (Hede, 2010).
Healthcare disparity in NSCLC among Hispanics is not well understood. There
are few studies in the literature that describe the disparities experienced by Hispanics in
the treatment of lung cancer, and when Hispanics are included in the studies they are
usually underrepresented (Saeed, 2012). Two studies, one using the SEER database and
the other study using the California Cancer Registry evaluated survival outcomes in
Hispanics with NSCLC (Patel et al., 2013; Saeed et al., 2012). Foreign-born Hispanics
were compared to U.S. born Hispanics. Patients were evaluated based on several
confounders such as, age, gender, stage of disease, SES, and the neighborhood where
they lived. The results from these two studies demonstrated that foreign-born patients
with NSCLC had a 13% to 15% (HR, 0.85- 0.87) lower mortality rate than patients born
in the United States (Patel et al., 2013; Saeed et al., 2012). When patients were evaluated
by tumor histology, Hispanic patients were found to have either adenocarcinomas or
bronchioalveolar (BAC) tumors. BAC tumors have a more favorable profile and a lower
mortality rate (Patel et al., 2013). Lung cancer patients who were foreign-born were 40%
more likely to be diagnosed at a more advanced stage of disease, at an earlier age, and
less likely to receive treatment for their cancer (Patel et al., 2013; Saeed et al., 2012).
U.S. born Hispanics had a lung cancer survival rate equivalent to non-Hispanic White
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lung cancer patients (HR, 1.00). While foreign-born Hispanics have a lower SES than
U.S. born Hispanics, they still maintained a survival advantage over U.S. born Hispanics.
One possible reason for the differences in survival between foreign born and U.S. born
Hispanics could be the acculturation of Hispanics born in the United States or that
foreign-born Hispanics return to their country of origin when they become too sick; but
the survival patterns did not validate this trend (Patel et al., 2013). A meta-analysis of 58
studies from 1990 to 2010 showed that Hispanics with cancer have a survival advantage
that is equivalent to non-Hispanic Whites (Ruiz, Stefan, & Smith 2012).
Insurance Status
Insurance status has been shown to be a predictor for determining access to cancer
care and receiving appropriate care (Shugarman et al., 2009; Ward et al., 2008).
However, the evidence is mixed as there are few studies evaluating the association of
insurance status and cancer treatment outcomes and even fewer studies specifically in
lung cancer. During the past decade research has shown that patients who are
underinsured or uninsured had worse treatment outcomes than patients with private
insurance (Harlan et al., 2005; Niu et al., 2013). Harlan evaluated the association of
insurance and cancer outcomes in 11 different cancers and found that patients without
insurance or patients with private insurance had better outcomes than patients with either
Medicare or Medicaid. An article recently published by Nui and colleagues (2013) found
that between 1995-2004, cancer patients in New Jersey with Medicaid or who were
uninsured had a higher risk of death than patients with private insurance. These findings
concur with a number of other studies previously conducted (Blackstock et al., 2002;
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McDavid, Tucker, Slogett, & Coleman, 2003; Ward et al., 2008). When Harlan et al.
(2005) evaluated a variety of cancers for treatment according to the clinical guidelines
and according to insurance status; they found that the type of insurance patients had
influenced treatment according to the recommended guidelines. Patients with private
insurance were more likely to receive cancer treatment according to the guidelines
regardless of race/ethnicity than patients on Medicaid or Medicare (Harlan et al., 2005).
Patients with Medicaid insurance only were the least likely to receive therapy according
to the guidelines while patients with no insurance or private insurance were most likely to
receive treatment according to the clinical treatment guidelines, 70%, and 65%
respectively. Blackstock et al. (2006) and ascribed that when insurance status, economic
status, stage of disease, and age are equal, treatment for early stage NSCLC with
chemotherapy and/or surgery outcomes are similar.
To answer the question of which factors have a greater influence on patient’s
healthcare, Trevedi et al. (2006) investigated whether the quality of the insurance plan or
the race/ethnicity of the patient affected health outcomes more. Trevedi et al. examined
health records from over 400,000 patients on over 150 Medicare plan between 2002-2004
for quality and performance and revealed that neither the insurance plan nor the quality or
performance contributed to disparities. Despite having the same insurance plan,
significant disparities were found between African American and Caucasian health
outcomes (Trevedi et al., 2006). Halpern et al (2008) also found that insurance status
influenced cancer treatment and that individuals over 65 years of age with Medicare do
not receive equal treatment, even though the stage of cancer at the time of diagnosis was
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similar across insurance types. In a second study, Halpern and Holden (2012) found that
insurance status also influenced the timeliness of cancer treatment; African Americans
and Hispanics were found to experience treatment delays more often than Caucasians.
Patients having both Medicaid and Medicare coverage still experienced delays in
treatment. When universal insurance coverage is available, disparities still exist in cancer
treatment (Li et al., 2011). Yorio et al. (2012) indicated that when patients are treated at
VA Hospital or an NCI designated cancer center differences in overall survival appear to
disappear. Differences in insurance status may contribute to cancer outcomes; however,
additional research is needed in this area to overcome the disparities in care experienced
by patients with lung cancer (Halpern & Holden, 2012).
A robust example for comparison is the medical system for the U.S. military,
which provides unlimited and equal access to healthcare and can provide an opportunity
to evaluate healthcare disparities under equal conditions. In an effort to evaluate if there
is disparity in lung cancer survival between men and women and between race/ethnicity
of military personnel, Mulligan et al (2006) conducted a retrospective chart review of 907
NSCLC patients treated at Walter Reed Medical Center from 1990 to 2000. Patient
survival was analyzed by age, gender, race/ethnicity, family history of cancer, smoking
history, stage of disease, and lung cancer histology. The overall survival of NSCLC
patients treated at Walter Reed Army Medical Center were compared to the overall
survival of NSCLC patients in the SEER database for 2000. The overall 5-year survival
at Walter Reed was higher than the 5-year national average for survival in the SEER
database, 22.4% versus 15.2 % respectively (Mulligan et al., 2006). The 5-year survival
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for African Americans versus Caucasians was essentially equal at 22.3% versus 22.7%.
Even when survival was evaluated by gender, survival was higher for the Walter Reed
Army Medical Center patients compared to the national average in SEER. Gender was
the only factor that affected 5-year overall survival with females having a longer survival
than males, 28.9% versus 19.4% (Mulligan et al, 2006). Mulligan and colleagues suggest
that when there is equal access to healthcare, health outcomes are equal implicating a
lack of access to medical care as a cause for racial/ethnic disparities. A larger study
conducted by the Department of Defense using their central tumor registry database
confirmed the results of Mulligan and colleagues indicating that NSCLC survival is
higher in a military facility than the general population and that equal access to care may
eliminate health disparities (Zheng et al., 2012).
Which factors are contributing to lung cancer disparities and how these factors
affect each other remain unclear. Lung cancer treatment appears to vary by place of
treatment, utilization of health care services, institutional policies, race/ethnicity, gender,
and socioeconomic status. Having standards of care established and guidelines in place
may help to eliminate some of the differences in treating NSCLC and reduce healthcare
disparities.
Socioeconomic Status, Race, and Environmental Factors
There are considerable data in the literature documenting that race and
socioeconomic status affect mortality; however, there is less data on how these factors
impact cancer mortality in patients with lung cancer. Albano et al. (2007) sought to
determine if there was a relationship between education, race/ethnicity, and mortality in
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cancer patients, including lung cancer, by using U.S. census data and death certificates
from African American/Black and Caucasian cancer patients in 47 states. Overall, the
death rate for African Americans was higher than for Caucasians at comparable
educational level. Albano and colleagues contribute the difference in mortality to the
differences in overall socioeconomic status between the two groups (Albano et al., 2007).
When lung cancer mortality was evaluated, the difference between African American and
Caucasian patients by educational attainment was greater than for other cancers that were
evaluated. Patients with an educational level of 0 to 8 years had a mortality rate that was
nine times higher than patients with educational attainment of 17 or more years and was
higher in African American men and women as compared to Caucasian men and women
(Albano et al., 2007). Albano and colleagues (2007) found a stronger association
between educational level and cancer mortality than in previous studies.
There are considerable data to show that the geographic area one lives in
influences the quality of health care and mortality (Myers, 2007). Research suggests in
areas of low socioeconomic status that there may be fewer resources available, that the
healthcare providers maybe less educated and that patients may not receive timely and
appropriate therapy (Goulart et al., 2013). Referrals to medical specialists have also been
shown to influence cancer care. Patients in a lower socioeconomic group are also less
likely to be referred to an oncologist or to receive recommended therapy as compared to
patients in a higher socioeconomic group (Goulart et al., 2013; Freeman & Chu, 2005).
Life expectancy, the geographic location, the number of healthcare providers in an area,
and treatment variation play a role in healthcare treatment and can contribute to the
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disparities experienced by minorities (Meyers 2007; Watson, 2001).
Cognitive Factors
A healthcare providers’ perception can affect the care patients receive. According
to the SCT, physicians contribute to health disparities through stereotyping and bias that
reflects in the quality of care (Smedley, 2003; Burgess et al., 2004). The SCT theory
suggests that the healthcare providers understanding of the information provided by the
patient and how the information obtained is interpreted may contribute to racial/ethnic
differences in care and outcomes (Meyers, 2007; Burgess et al., 2004). Consciously or
unconsciously healthcare providers express biases and categorize individuals according
to characteristics, social categories, and stereotypes (Burgess et al., 2004). Healthcare
providers also make judgments about how a patient will follow through with treatments
(Burgess et al., 2010). Several studies revealed that Caucasian healthcare providers
perceive African Americans as having less family support and as being less compliant to
treatments long-term (Bogart et al., 2004; van Ryn et al., 2003).
When physicians process large amounts of complex information to make clinical
decisions, they tend to act on what they have already learned and already know,
especially when there may be insufficient information available about the best treatment
to provide to a patient thereby causing the potential for errors in diagnosis and treatment
(Freeman & Chu, 2005; Burgess et al, 2004). These decisions in turn also have the
ability to affect the communication between the clinician and the patient and adherence to
therapy (Burgess et al., 2010; Smith, 2000).
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Behavioral Factors
According to the SCT, an individual’s behavior is influenced by the behaviors and
thoughts of others’ around them (Pajares, 2002). Studies in SCT have examined
healthcare provider behaviors to understand how race/ethnicity affects treatment.
Physician treatment patterns are influenced by their medical training, background, by the
variety of medical experts whom they interact, by their mentors, by medical ethics, and
by other colleagues (Smith, 2000). In addition, stereotypes by healthcare providers have
been shown to influence the patient. If a patient feels they are being discriminated
against or the physician exhibits anxiety, the patient may not communicate openly with
the physician, may not share information about their illness, and may even be less
complaint to treatments (Burgess et al., 2010; Smith, 2000). Blair et al. (2013) conducted
telephone interviews with patients to determine the perception and satisfaction with their
physician. African Americans consistently reported more bias on the part of the
physician and more dissatisfaction with care. Hispanics/Latinos did not report bias but
consistently rated the physician lower on knowledge of their health concerns, medical
history, and interpersonal skills (Blair et al., 2013). Providing continuity of care through
the use of clinical practice guidelines may improve the quality of care patients receive
(Penner et al., 2007).
Tumor Boards
Tumor boards serve an important role in cancer programs and there are data
reported that they might improve cancer care (Scher et al., 2011). Tumor boards bring
physicians and other healthcare providers together from medical oncology, radiation
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oncology, pathology, radiology, surgery, and other allied health specialties to discuss the
management and care of the newly diagnosed patient. Physicians from their respective
discipline present the current treatment strategies appropriate for the patients’ cancer and
discuss the current clinical trial data to help guide the treatment course for the patient.
All NCI designated cancer programs have either general or tumor specific tumor boards
as required by the American College of Surgeons Commission on Cancer Program
Accreditation but their effect on cancer care has not been well studied. (Keating et al,
2012). Some controversy exists as for the value of tumor boards improving quality care
based on the physician recommendations provided from the tumor board. The
Department of Health Policy at Harvard Medical School evaluated the association
between the recommendations, quality of care and outcomes of patients in 138 Veterans
Administration (VA) Hospitals and physicians attending tumor boards and found there
was little to no association between physicians attending tumors boards, between the
recommended treatment patients received and outcomes (Keating et al., 2012). Other
researchers have noted that tumor boards may not influence physician treatment and
outcomes in large institutions, but may be more effective in small cancer centers
(Blayney, 2012). However, Scher (2011) found that over 80% of physicians attended
tumor boards when they are offered and that tumor boards provide a way for physicians
to discuss the treatment of difficult patient cases as a way to improve the quality of care
(Scher, 2011). Physicians with high volume practices, treating 25 or more new patients
per month were more likely to attend tumor boards (Scher, 2011). Additional research is
still needed to determine the characteristics of the physicians attending tumor boards and
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the influence of tumor boards on physician treatment patterns and clinical guideline
adherence (Blaney, 2013; Keating et al., 2013; Scher, 2011).
Addressing treatment differences and disparities in lung cancer is complex and
involves multiple factors that cannot be defined by one theory. Preliminary research in
NSCLC healthcare disparities is mixed and this suggests that further research is needed.
If practice guidelines are available and followed to influence clinical decision making,
there may be fewer disparities seen between races/ethnicities.
While most of the research regarding disparities in lung cancer is focused in the
earlier stages of the disease and compares African Americans and Caucasians, this
research study will address how the current treatment guidelines available for NSCLC
guidelines are used in a population-based patient population that includes Hispanics.
Hispanics continue to rapidly increase in the United States yet represent a smaller
percentage of the patients in the SEER database. To gain a better understanding of the
treatment paradigms’ within this ethnic group they should be included in treatment and
disparities research. This research study will include an evaluation of Hispanic patients
with advanced metastatic NSCLC since there is little research about the treatment
paradigms of these patients.
This research study will build on what is currently known about treating advanced
stage NSCLC in a diverse population of Hispanics, African Americans, and Caucasians.
Specific chemotherapy and targeted therapies will be evaluated for their use in NSCLC
and if they are used according to the current clinical practice guidelines within each of
the racial/ethnic groups.
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Summary and Conclusions
This chapter describes some of the multiple factors involved in healthcare
disparities. Although research has been conducted on cancer disparities, the causes for
these disparities still are not well understood, particularly among Hispanics. The SCT
and Bandura’s self–efficacy model suggest that physicians unconsciously contribute to
health disparities. Previous research on disparities in lung cancer has been conducted on
the comparisons between African Americans, who have the greatest lung cancer burden,
to Caucasians in the earlier stages of the disease. The research also revealed that despite
equal socioeconomic status and equal insurance coverage differences in cancer care and
outcomes remain. There is limited data studying the treatment paradigms and differences
in treatment and care among Hispanics and African Americans as compared to
Caucasians in the later stages of NSCLC. This study will attempt to fill the gap and focus
on evaluating the use of lung cancer clinical treatment guidelines in patients with
advanced/metastatic NSCLC between Hispanics, African Americans, and Caucasians.
This study has considered the limitations and will therefore evaluate patients for
treatment patterns and to determine if there is a relationship between race/ethnicity and
lung cancer treatment according to the NCCN clinical practice guidelines.
Since healthcare professional’s training and behaviors have been shown to
contribute to the disparities, having clinical practice guidelines available to physicians
treating patients is a first step in an attempt to reduce racial and ethnic differences in the
treatment of disease. Having an understanding of the extent to which NSCLC clinical
practice guidelines are consistently used across racial/ethnic groups, this research study
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may help to bring us closer to reducing the cancer burden in the United States and
improving care for all patients.
Chapter 2 provided the background on healthcare disparities and the literature as
it related to the research questions and hypotheses, and the objective of the study.
Chapter 3 outlines the quantitative research methodology that was used for this study. A
description of the study hypotheses based on the research questions will be explained. A
description of the retrospective research design, the dependent, and independent study
variables, a description of the NCI database that was used, the techniques for the data
collection, and data analysis are included. The determination of sample size and a
description of the patients are explained. The relationship between race/ethnicity for
initial advanced lung cancer treatment and the use of clinical treatment guidelines are
determined.
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Chapter 3: Research Method
Introduction
Lung cancer is a major killer in the United States with approximately 155,000
patients dying from the disease each year (ACS, 2014). It is primarily a disease of the
elderly with over 60% of patients diagnosed with lung cancer over 65 years of age
(Foster, Salinas, Mansell, Williamson, & Casebeer, 2010). With the complexities of
treating lung cancer and the new diagnostic technologies being developed, clinical
treatment guidelines constantly need to be updated to include the newest research
discoveries, physicians need to be aware of the updates and be able to incorporate the
guidelines to their clinical treatment decisions.
In this chapter, I provide an overview of the research methodology used in this
study to test the hypotheses and answer the research questions around the first-line
treatment for NSCLC in three racial and ethnic groups according to the NCCN treatment
guidelines. I also describe the research hypothesis and questions. In addition, a
description of the study population, the procedures for selecting the sample population
and determining the sample size, a description of the inclusion and exclusion criteria, an
explanation of the study variables, and details of the statistical plan are provided. This
chapter also includes a discussion of issues pertaining to reliability and validity of the
study and the data collected from the SEER/Medicare database. The chapter concludes
with the ethical considerations for this research.
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Purpose of the Study
The purpose of this retrospective quantitative study was to evaluate the
differences among Caucasian, Hispanic, and African Americans with NSCLC within
strata as defined by stage and histology and the receipt chemotherapy for the first-line
treatment of advanced/metastatic NSCLC treatment according to clinical practice
guidelines while controlling for age and gender. For this study, patients were stratified
into four groups: (a) stage IIIB disease and adenocarcinoma; (b) stage IIIB and squamous
cell carcinoma; (c) stage IV disease and adenocarcinoma; and (d) stage IV disease and
squamous cell carcinoma.
Research Design and Rationale
Research Question
To understand the association between race/ethnicity and the receipt of first-line
treatment of advanced/metastatic NSCLC according to the recommended NCCN clinical
practice guidelines for stage and histology strata, the following research question was
asked: What is the likelihood of Caucasian, African American, and Hispanic patients with
NSCLC being equally treated according to the NCCN practice guidelines within stage
and histology strata after controlling for age and gender?
Evidence suggests that there may be an association between race/ethnicity and the
receipt of first-line therapy for advanced/metastatic NSCLC and physicians following
clinical practice guidelines. Therefore, the following hypotheses were evaluated.
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Null and Alternative Hypotheses
1. Ho: Caucasian and African American patients with NSCLC are equally likely to be
treated according to the NCCN treatment guidelines within stage and histology strata
after controlling for age and gender, and geographic location.
H1: Caucasian and African American patients with NSCLC are not equally likely to
be treated according to the NCCN treatment guidelines within stage and histology after
controlling for age and gender, and geographic location.
2. Ho2: Caucasian and Hispanic patients with NSCLC are equally likely to be treated
according to the NCCN treatment guidelines within stage and histology strata after
controlling for age, gender, and geographic location
H12: Caucasian and Hispanic patients with NSCLC are not equally likely to be
treated according to the NCCN treatment guidelines within stage and histology strata
after controlling for age, gender, and geographic location
3. Ho3: Hispanic and African American patients with NSCLC are equally likely to be
treated according to the NCCN treatment guidelines within stage and histology strata
after controlling for age, gender and geographic location
H13: Hispanic and African American patients with NSCLC are not equally likely to
be treated according to the NCCN treatment guidelines within stage and histology strata
after controlling for age, gender, and geographic location
Dependent and Independent Variables
The dependent variable for this study was receipt of first-line treatment with
chemotherapy according to NCCN treatment guidelines (i.e., receiving either taxane plus
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platinum, gemcitabine plus platinum, pemetrexed plus platinum, or the triple combination
of bevacizumab plus platinum-based therapy for stage IV NSCLC and platinum plus
etoposide alone or concurrent radiation and platinum plus etoposide for stage IIIB
NSCLC based on histology). The predictor variables were age (65-70, 71-75, 76-80, 8185, and 85 and older), gender (male, female), and race/ethnicity, which were recorded as
Caucasian, African American, or Hispanic (see Table 1). Patients were stratified by stage
of disease and histology into four groups: stage IIIB disease with either adenocarcinoma
or squamous cell carcinoma and stage IV disease with either adenocarcinoma or
squamous cell carcinoma. Stage IIIB NSCLC was defined as patients with disease that
has spread to the lymph nodes near the collarbone or to the nodes on the opposite side to
the tumor, patients with a pleural effusion, or with disease that has spread to other areas
within the chest, such as the esophagus or trachea. Patients with stage IV NSCLC have
disease that has spread outside of the chest wall to other parts of the body such as the
bone, liver, or brain, or has spread to other distant lymph nodes. Recommended and
appropriate therapy for stage IIIB NSCLC is radiation plus chemotherapy or
chemotherapy alone. Recommended therapy for stage IV NSCLC is a doublet
combination of chemotherapy (NCCN, 2014). There are no recommendations for the
administration of a specific chemotherapy with the exception of pemetrexed, which is
indicated for adenocarcinoma histology and gemcitabine for squamous cell histology
(NCCN, 2014). Although the approach to treating older cancer patients is unclear, age
has been found to be an influencing factor in treating patients with advanced/metastatic
NSCLC. The benefits of treatment outweigh the risk, yet many cancer patients are
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undertreated (Foster et al., 2010). Foster et al. reported that patients over the age of 78
were less likely to receive standard chemotherapy than patients younger than 60 years of
age, despite being in relatively good health. While there is not a specified time period in
which treatment should be initiated, starting therapy as soon as possible after diagnosis,
usually within a month, has been shown to improve outcomes (Yorio et al., 2009).
Initiating therapy within 45 days of diagnosis was used as the timeframe for this study.
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Table 1
Description of the Dependent and Independent Variables
Variable
Treatment according to NCCN
guidelines
1.
2.
3.
4.
5.
6.

Dependent
variables

Independent
variables

X

Characterization

Nominal
(yes or no)

Taxane/platinum
Taxane/platinum/ Bevacizumab
Pemetrexed/ platinum
Gemcitabine/ platinum
Radiation
Radiation/ chemotherapy

Stage of disease
X
Stage IIIB

Stratification variable
Categorical

Stage IV
Age, yrs
X

Interval/grouped

X

grouped
Nominal

Gender
Male
Female
Histology
Adenocarcinoma

Stratification variable
X
Categorical

Squamous cell
Race
Caucasian

X

Referent group

Hispanic

Dummy Variable

African American

Dummy Variable
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Adherence to NCCN Clinical Practice Guidelines
Adherence to the NCCN clinical practice guidelines for this study was based on
the patient stage of disease and tumor histology. Most patients with stage IIIB disease
are not eligible for surgery; therefore, treatment is based on the patient’s extent of
disease, performance status, and co-morbidities. Because performance status is not
captured in the SEER-Medicare database, patient histology and extent of disease based
on stage of lung cancer was used to determine appropriate treatment. The NCCN clinical
treatment guidelines recommend concurrent radiation, platinum, and etoposide or
radiation with paclitaxel and platinum chemotherapy for patients with stage IIIB NSCLC
(Figure 1). The recommended dose of radiation is 60-70 Gy over 6-7 weeks. Radiation
alone can be used as palliation to treat pulmonary symptoms such as pain or shortness of
breath (NCCN, 2013). Based on the clinical data nonplatinum-based chemotherapy does
not provide a treatment benefit over platinum based therapy (Lwin, Riess, & Gandara,
2013; NCI, 2014).
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Stage IIIB
NSCLC

Chemotherapy
plus radiation

Radiation
Alone

Chemotherapy
Alone

Figure 2. Treatment Algorithm for Stage IIIB NSCLC based on the NCCN NSCLC
Guidelines.
Patients with stage IV NSCLC have metastatic disease at the time of diagnosis.
The goal of treatment is to extend survival and palliate symptoms from the disease
(NCCN, 2014). Performance status is one of the most important prognostic factors for
outcomes; however, performance status is not currently captured in the SEER-Medicare
database. Therefore, treatment according to the recommended treatment guidelines was
determined by histology. The NCCN treatment guidelines recommend a platinum-based
chemotherapy doublet as first-line treatment of stage IV NSCLC; however, there are no
definitive combinations recommended (NCCN, 2014).
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Stage IV NSCLC

Squamous cell

Adenocarcinoma

Platinum based
chemotherapy
with
gemcitabine or
with a Taxane

Platinum based
chemotherapy
with a taxane or
with pemetrexed

Bevacizumab

Figure 3. Treatment Algorithm for Stage IV NSCLC based on the NCCN NSCLC
Guidelines.
Treatment for stage IV NSCLC is recommended for four cycles and if the patient
is responding may receive two additional cycles, for not more than a total of six cycles of
therapy in the first-line setting. A triple combination of paclitaxel, carboplatin, and
bevacizumab is recommended for patients with nonsquamous histology
(adenocarcinoma) if the patient does not have a centrally located lung tumor. However,
other triplet combinations are not recommended because of the added toxicity and have
not been found to offer a survival advantage over the doublet regimens (NCCN, 2014).
The combination of pemetrexed plus platinum chemotherapy is recommended for
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patients with adenocarcinoma, whereas gemcitabine or a taxane plus platinum
chemotherapy is recommended for patients with squamous histology (Azzoli et al, 2011).
Radiation is recommended for patients with stage IV NSCLC for palliation of symptoms
from the disease, such as bone metastases or for brain metastases (NCCN, 2014). The
NCCN clinical practice guidelines for stage IIIB and IV NSCLC have change overtime.
The two differences from 1998 to 2014 are that histology matters. Patients are now
treated differently based on the histology of the tumor and the duration of treatment for
stage IV NSCLC was shortened in 2003 from a maximum of eight cycles of therapy to no
more than six cycles of therapy. If the patient is not responding to therapy it should be
stopped at four cycles.
Treatment information for up to 6 months after diagnosis was confirmed based on
the International Classification of Disease 9th edition Clinical Classification (ICD-9-CM)
procedure codes and certain ICD-9-CM codes for lung cancer diagnosis, International
Classification of Disease for Oncology, third edition (ICD-O-3) code was used for
NSCLC (8046), as well as SEER therapy codes, and revenue codes in the Medicare
database. Chemotherapy administration codes for each chemotherapeutic agent,
cisplatin, carboplatin, gemcitabine, pemetrexed, bevacizumab, paclitaxel, and docetaxel
were used to determine treatment against the NCCN clinical guidelines. If a patient
received a claim for concurrent cisplatin, etoposide and radiation or cisplatin plus
etoposide on the same date of service they were considered to have received therapy
according to the NCCN clinical practice guidelines. For stage IV disease, if a patient
received a claim on the same date of service for a combination of cisplatin plus a taxane,
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pemetrexed plus platinum, gemcitabine plus platinum or a taxane plus platinum plus
bevacizumab they were considered to have received treatment according to the NCCN
clinical practice guidelines.
Methodology
Population Characteristics
To be included in the study patients had to have a confirmed diagnosis of
NSCLC, have stage IIIB/IV NSCLC, and be age 65 years or older at the time of
diagnosis. Patients were of Caucasian, African American, or Hispanic race/ethnicity and
stratified based on stage of disease and histology into four groups. The four groups will
be stage IIIB with adenocarcinoma or squamous cell carcinoma and stage IV disease with
adenocarcinoma or squamous cell carcinoma. Other factors that were adjusted for based
on treatment were gender and age to determine the influence of these variables on the
likelihood of receiving first line treatment according to the NCCN clinical practice
guidelines. All patients were covered only by Medicare insurance at the time of
diagnosis as patients covered by a HMO or other type of insurance may have different
patterns of care.
Sampling Procedures
Patients were extracted from the linked SEER-Medicare database. A total of
250,045 lung cancer patients were included in the SEER-Medicare database. In order to
draw valid conclusions about the data from this study the following statistical parameters
were applied. The sample for this research consisted of all Medicare patients age 65
years or older who were diagnosed with NSCLC between 1998-2010 and filed a
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Medicare claim during this same time period. Patients were selected based on the
International Classification Disease for Oncology (ICD-O-3) code for NSCLC. SEER
provides data on patient demographics, cancer stage, histology, and date of diagnosis.
Medicare claims provide chemotherapy administered, and first treatment beginning and
ending dates. The month and year were used to determine date of diagnosis. The
MEDPAR, physician, and DME claims data were used to gather information about
chemotherapy treatment. The NCH files were used to find radiation claims. The dose of
radiation received was not provided but the duration of therapy was provided. Nursing
home records, health maintenance organization records, and Medicare denied claims
were omitted from the MEDPAR database. The drug specific codes were identified for
paclitaxel, docetaxel, cisplatin, carboplatin, pemetrexed, gemcitabine, vinorelbine, and
bevacizumab as well as the treatment code for radiation. Patients were coded as “yes or
”no” as having received the recommended treatment combination in the first-line setting
or did not receive recommended combination treatment.
Sample Size and Statistics
The study objective was to detect whether a statistically significant difference
exists between race/ethnicity within strata defined by tumor stage and histology,
according to the first line treatment of NSCLC according to the NCCN clinical practice
guidelines while controlling for age and gender. This study used multivariable logistic
regression to determine if there were differences in the first line treatment of lung cancer.
Regressions models were developed for each of the strata of stage and histology. A
binary logistic regression model was appropriate as the dependent variable is
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dichotomous and there were one or more independent variables. To determine if a
statistically significant difference existed the statistical power, alpha, and effect size was
determined. A high statistical power improved the chance that the results were not due to
chance alone. The minimum accepted value for power (1-ß) is 80% (0.8) meant that
there was an 8 out of 10 chance of rejecting the null hypothesis. The alpha for this study
was set at .05 for a two-tailed test, which meant there was be a 95% chance the correct
conclusion will be reached. The confidence level was set at 95% and statistical
significance p < 0.05. An adjusted odds ratio (OR) representing the odds for receiving a
given treatment type by race/ethnicity as a function of age, stage of disease and histology
was determined, and the corresponding 95% confidence interval (95% CI) was
calculated. If the OR was statistically equivalent to “one” or unity (e.g., 95% CI for the
adjusted OR contains 1 and the p value for the adjusted OR is greater the 0.05) there was
a difference for a particular treatment as the first line therapy between two racial/ethnic
groups. If the OR was statistically different from “one” or unity (e.g., 95% CI for the
adjusted OR does not contain 1 and the p value was less than 0.05) there was a difference
for a particular treatment type in the first line setting between racial/ethnic groups. All of
these statistical parameters were the standard norm in epidemiologic and biomedical
research (Dakhale, Hiware, Shinde, & Mahatme, 2012). G* Power was the statistical tool
to determine power analyses and effect size for a variety of statistical tests (Faul,
Erdfelder, Buchner, & Lang, 2009). Power analysis for a logistic regression was
conducted using the G*Power 3.1 statistical power calculator to determine the sample
size based on an alpha = 0.05, ß = 0.80, 2-sided tails, and an odds ratio = 1.44. To detect
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a small size effect an odds ratio of 1.44 was assumed (Nandy, 2012). This study
provided adequate number of patients and power to detect a difference between
race/ethnicity.
Data Source
The NCI SEER/Medicare database links the demographic and tumor data from
the SEER database with the Medicare claims filed from the CMS. SEER collects data
from 18 cancer center registries throughout the United States that represents 28% of the
U.S. population (NCI, 2013). SEER data are available from 1973 to 2013 and Medicare
data are available from 1991 to 2010 (NCI, 2013). The patients selected for inclusion in
this study were diagnosed with stage IIIB/IV NSCLC from 2009 to 2013. Patients
diagnosed by a death certificate were not included. SEER data are available for patient
age, gender, race/ethnicity, tumor site, stage of disease, tumor histology, date of
diagnosis, and initial treatment. All Medicare claims have fields for race, gender, date of
service, as well as diagnostic and procedure codes (Warren et al., 2002). In addition, the
SEER-Medicare claims data include claims from the hospital, outpatient clinics,
physicians, home healthcare, and hospice providers (Warren et al, 2002). Medicare
claims data were used to obtain the specific chemotherapy administered. SEERMedicare data are available for 93% of participant’s age 65 or older (NCI, 2013, Engels
et al., 2011). Ninety-six percent of individuals enrolled in Part A Medicare also have Part
B Medicare coverage, which covers physician and outpatient services (NCI, 2013). The
Medicare claims data were used to identify the chemotherapy administered. The
individual drug codes were used to identify chemotherapy administration. Using this
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large database will provide a better understanding of real world patterns of care among
NSCLC patients of different races/ethnicities and is more representative of the elderly
population who carry most of the burden of NSCLC. The SEER database does not
collect data from patients with Medicare as a second insurer, patients enrolled in an
HMO, or patients receiving care at a Veteran Administration Hospital (NCI, 2012).
Inclusion Criteria
Patients from the SEER-Medicare database were included in the study if they had
a confirmed diagnosis of NSCLC from 1998–2010, were age 65 years or older, were
treated within 6 months of diagnosis, and if there was at least one claim filed for
chemotherapy. The characteristics of the study cohort for inclusion to the study are,
1. Age, 65 years and older
2. Gender, male and female
3. Race, Caucasian, African American, and Hispanic
4. Histology, adenocarcinoma and squamous cell carcinoma
5. Stage of disease, stage IIIB and stage IV
Patients in the SEER database were excluded from study if they were diagnosed
with NSCLC before the age of 65 years. Patients younger than 65 years of age were not
included in the Medicare database however they may be included in the SEER database.
Most patients with lung cancer were diagnosed with advanced stage disease, as such,
patients with a diagnosis of stage I, II, or IIIA NSCLC at age 65 were excluded from the
study cohort. Patients with a diagnosis of NSCLC prior to the enrollment in Medicare
were excluded as they may be treated differently from Medicare patients. Patients with a
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diagnosis of small cell lung cancer, a concurrent cancer, or any other previous cancer
were excluded. Patients with end-stage renal disease or a medical disability are covered
under Medicare; however, these patients were excluded from this study. Patients with
missing data for any of the study variables were categorized as unknown and not included
in the analysis, i.e., there was not imputation for missing data. Patients of Asian,
American Indian/Native Alaskan, Native Hawaiian, or other Pacific Islander
race/ethnicity were not included in the study cohort. The Alaska and Arizona registries
were excluded from analysis as SEER only captures information on American Indian and
Alaska Natives in these states (NCI, n.d.).
Gaining Access to the Data
The SEER-Medicare database is a large population cohort of cancer patients that
allows for the longitudinal study of treatment procedures and treatment administration.
The database has been used extensively for disparity research and outcomes research and
is a standard tool that researchers use to evaluate patterns of care and outcomes in
oncology (Clegg et al., 2007). The database is also used for studies in public health
policy and planning (Engels et al, 2010; NCI, 2010).
Because the SEER-Medicare linked database is not open to the public permission
must be granted for its use in research and to also maintain the confidentiality of the
patients and the healthcare providers. The SEER- Medicare data set is considered a
limited dataset by Health Insurance Portability and Accountability Act (HIPPA) and as
such a data use agreement for requesting lung cancer data was signed by the committee
chairperson and myself prior to receiving access to the SEER-Medicare files. A Walden
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IRB approved proposal was submitted to the SEER-Medicare reviewers for approval
prior to the release of the requested databases.
Data Analysis
A multivariable logistic regression was conducted to analyze the data from the
SEER-Medicare database, using the Statistical Packages for the Social Science (SPSS).
Baseline demographics and patient clinical characteristics were analyzed using measures
of central tendency (e.g., means, medians) and spread (standard deviations, SD; range)
and frequency counts and percentages for categorical variables (e.g., gender).
Race/ethnicity, age, and gender were the independent variables that determined the
treatment in the first line setting. The dependent variable was dichotomous and defined
as either “yes” or “no” (e.g., patient received taxane plus platinum vs. patient did not
receive taxane plus platinum). Patients were stratified according to stage of disease and
histology and within each strata age and gender were controlled. Univariate and
multivariate regression analysis were performed to compare the likelihood of receiving
treatment according the practice guidelines within stage and histology strata. A
regression analysis tested if the criterion variable was linearly related to the covariates of
age and gender. In order to understand the variance in the dependent variables a table
was developed for R2. A classification table was developed to estimate the percent of
cases correctly classified as receiving first-line treatment with each independent variable
added to the model, the probability of the outcome occurring, the sensitivity, and
specificity. A third table showed the contribution of each independent variable to the
regression model and its statistical significance. The p values were evaluated for each
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covariate to determine the statistic evidence for the contribution to the model. The OR
indicated the likelihood of receiving the recommended treatment based on the clinical
practice guidelines and based on the independent variables. The confidence intervals
were established using the odds ratio. The final logistic regression model pooled the
observations according to probabilities assessed with the goodness-of-fit statistic (Homer
& Lemeshow, 1989). Missing data was not included in the final analysis thereby
allowing for a complete case analysis to be conducted (Piggott, 2001). This study was
exploratory in nature and therefore there was no adjustment for multiplicity. It was
recognized there was the potential for inflated type I error; this is discussed in Chapter 5.
All statistical analyses were performed using IBM SPSS 23.0 (IBM SPSS Statistics 23.0
August 2016, Armonk, NY).
Instrumentation and Operationalization Constructs
The NCI’s SEER database is the one of the largest population-based cancer
databases in the U.S. and is considered that standard for quality among cancer registries
(NCI, 2010). Since 1972 SEER has collected data and monitored cancer trends, cancer
incidence, diagnosis, therapy, and survival (NCI, 2010). SEER collects cancer data from
select state tumor registries (Alaska, Arizona, California, Connecticut, Georgia, Hawaii,
Iowa, Kentucky, Louisiana, Michigan, New Jersey, Utah, and Washington) that cover 18
geographic regions to represent the diverse population in the U. S (NCI, 2010; Engels et
al, 2010). While the database may represent the diverse race/ethnicities in the United
States, the database tends to represent more urban than rural areas (Engels et al, 2010).
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SEER also contains slightly more foreign-born cases (18%) as compared to13% in the
general U.S. population (NCI, n.d.).
Reliability and Validity
The SEER-Medicare database allows for the longitudinal study of treatment
procedures and treatment administration. The database has been extensively used for
disparity research and outcomes research and is a standard tool that researchers use to
evaluate patterns of care and outcomes (Clegg et al., 2007). The database is also used for
studies in public health policy and planning (Engels et al., 2010; NCI, 2010).
The reliability of the data from the SEER database has been previously reported
(Abel, 2011; Engels et al., 2010). The SEER-Medicare data have been used in over 900
previously published studies evaluating cancer patterns of care, quality of care, cost of
treatment, and cancer disparities (NCI, 2010). This NCI and CMS supported database is
one the largest and most comprehensive epidemiologic surveillance cancer databases that
contain over 1.6 million cancer patients. Maintaining the quality of the SEER data for
completeness and quality has been ongoing since the database was initiated in the 1970’s
(Clegg et al., 2007). As well the SEER-Medicare database is updated biennially (Engels
et al., 2010). Utilizing a large population database like the SEER-Medicare database
allows for tracking cancer overtime.
This study assessed the association between race/ethnicity and first line NSCLC
treatment and treatment according to the clinical practice guidelines; therefore, it was not
be possible to establish causation. Internal validity for a correlation study will be weaker
than for an experimental deign study. As with any retrospective study, data may be
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incomplete or inaccurate. For example, there may be limited or missing data on the use
of tobacco, performance status, or co-morbidities (Engels et al., 2010). Data regarding
age, date of diagnosis, stage of disease, and cancer histology in the SEER database were
found to be fairly accurate (Field, Smith & Lynch, 2004; Field et al., 2004). Utilizing the
SEER-Medicare database only allowed for generalization to the elderly population aged
65 years and older with NSCLC.
Ethical Procedures
Protecting patient information is of paramount importance with this study. An
informed consent from the patient was not required for this research study; however, all
reasonable measures were taken to protect the SEER-Medicare data. The database was on
a device that is password protected. To protect patient anonymity, certain data within the
SEER-Medicare database were restricted and not included as part of the files. These
variables include patient census track zip codes and the zip codes for physicians and
hospitals (SEER-Medicare, 2014). In addition, the hospital and physician name were
encrypted. The NCI and Walden University requirements regarding the protection of
patients, healthcare facilities, and providers were followed. The NCI requirements
regarding cell sizes were followed when conducting statistical analyses to prevent the
potential identification of patients. All files received from the NCI, SEER-Medicare
database for this research will be destroyed at the completion of the study as required by
the NCI and the NCI will be notified of destruction. As noted previously, approval from
the IRB at Walden University was necessary prior to requesting data from SEER. IRB
approval # 06-05-15-0174312 was granted. Approval by the SEER managers prior to
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initiating the data analysis was also necessary. A copy of the Data Use Agreement
(DUA) and the approval letter to use the SEER-Medicare database is provided in the
appendix (Appendix A). There are no conflicts of interest.
Summary
In summary, this quantitative retrospective study using the NCI SEER database
linked to the Medicare insurance database between 2009-2013 was conducted to answer
the question of the likelihood of being treated according to the NCCN treatment
guidelines in the first line setting taking into consideration race/ethnicity, age, gender,
stage of disease and histology. In the presence of clinical practice guidelines it is unclear
if disparities exist when treating NSCLC patients. Chapter 3 described the methodology
for this research study, including the overall study design, study population, sampling
techniques, data collection, and ethical considerations. Data analysis and issues
pertaining to reliability and validity of the SEER-Medicare database were also addressed.
Chapter 4 summarizes the data based upon the statistical analyses described in this
chapter. Chapter 5 provides a summary and interpretation of the study results and
recommendations for future research.
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Chapter 4: Results
Introduction
The purpose of this retrospective population-based cohort study was to evaluate
the relationship between Caucasian, African American, and Hispanic race/ethnicity, as
stratified by histology (squamous vs. adenocarcinoma), and stage of disease (stage IIIB or
IV) to the receipt of first-line treatment for NSCLC). To understand the differences in
treatment of first-line NSCLC by race/ethnicity, an evaluation of NSCLC patients aged
65 years and older was conducted using the NCI’s SEER-Medicare linked database.
SEER is the most comprehensive clinical database for cancer research and includes
patients’ demographic, clinical, and treatment information. SEER also provides
information on patients from across the United States receiving treatment in different
treatment centers, both community and academic centers, which makes the analysis more
representative of the total cancer patient population. The SEER database linked with the
Medicare database combines the patient clinical information with insurance claims and is
also the only source of population-based information in the United States that includes
stage of cancer at the time of diagnosis. The SEER-Medicare database allows for the
longitudinal study of patients 65 years and older over the course of their diagnosis and
treatment. The database also provides the power to evaluate regional treatment and
disparities among race/ethnicity.
The results of the data analysis in Chapter 4 are presented in tables to describe the
findings of the study. The demographic variables (age, gender, and geographic location)
were cross-tabulated by ethnic groups (Caucasians, African Americans, and Hispanics)
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for comparison. Descriptive statistics are shown based on each of the racial/ethnic groups
studied. Stage of disease and histology were considered possible confounding variables.
The results from the logistic regression analyses are described and organized by ethnicity
to provide comparisons for stage and histology.
The research question and hypotheses that were studied are as follows:
What is the likelihood of Caucasian, African American, and Hispanic patients
with NSCLC are being treated equally according to the National Comprehensive Cancer
Network (NCCN) practice guidelines within stage and histology strata after controlling
for age, gender, and geographic location?
H01:

Caucasian and African American patients with NSCLC are equally likely to be
treated according to the NCCN treatment guidelines within stage and histology
strata after controlling for age, gender, and geographic location.

H11:

Caucasian and African American patients with NSCLC are not equally likely to
be treated according to the NCCN treatment guidelines within stage and histology
after controlling for age, gender, and geographic location.

H02:

Caucasian and Hispanic patients with NSCLC are equally likely to be treated
according to the NCCN treatment guidelines within stage and histology strata
after controlling for age, gender, and geographic location.

H12:

Caucasian and Hispanic patients with NSCLC are not equally likely to be treated
according to the NCCN treatment guidelines within stage and histology strata
after controlling for age, gender, and geographic location.
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Ho3:

Hispanic and African American patients with NSCLC are equally likely to be
treated according to the NCCN treatment guidelines within stage and histology
strata after controlling for age, gender, and geographic location.

H13:

Hispanic and African American patients with NSCLC are not equally likely to be
treated according to the NCCN treatment guidelines within stage and histology
strata after controlling for age, gender, and geographic location.
This chapter details the data collection methods and the quantitative analysis

conducted. Under the research question the patient characteristics and the results are
described. A logistic regression analysis was conducted and the results were related to
the research question. Baseline descriptive statistics were also reviewed. The chapter
concludes with a summary section that provides answers to the research questions and
then transitions to Chapter 5.
Data Collection
For this study, I used a secondary analysis of data obtained from the NCI-SEER
database. After Walden University’s Institutional Review Board (IRB) approved the
research, a proposal was submitted to the NCI to obtain the SEER-Medicare data for
patients with lung cancer. After approving the proposal, the NCI provided a DVD with
the SEER and Medicare claims data sets for lung cancer for the years 2009 through 2013
for analysis. The data on the DVD were uploaded onto an external server where the data
were analyzed and stored for the duration of the analysis. The data were prepared and
analyzed using IBM-SPSS 23.0.

81
The SEER-Medicare database contained data on patients diagnosed with lung
cancer between 2009 and 2013. The inclusion criteria for the cases included having
tumors of the lung and bronchus as well as being at least 65 years of age at diagnosis.
Individual data for each case were collected included ethnicity age, gender, geographic
location, stage of disease (stage IIIB or IV), histology, and treatment. The independent
variables in this study were age, gender, stage of disease, histology, and geographic
location. The dichotomized response variable in the logistic regression model was
whether the treatment provided was in accordance with the NCCN treatment guidelines.
The initial sample size was 77,367 cases with 12,341 cases used in the logistic regression
model. Patients were excluded if they had stage I, II, or IIIA NSCLC, if they had a
previous or concurrent cancer other than basal cell carcinoma, had a lung cancer
histology other than adenocarcinoma or squamous cell carcinoma, were not enrolled in
Medicare Part A and Part B at the time of diagnosis, or were enrolled in Medicare as a
result of end-stage renal disease or disability and were less than 65 years of age. As a
result of these exclusion criteria, 14,882 cases were available for analysis. These cases
were then matched with their Medicare records and an additional 2,541 patients were
unable to be matched with Medicare claims, resulting in a final number of 12,341
patients. Figure 4 describes the selection process for patient inclusion.
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Total number of SEER patients with a diagnosis of NSCLC
N= 77,367
Exclude patients diagnosed stage with stage I, II, IIIA NSCLC
N= 34,050
Exclude patients with a diagnosis of small cell lung cancer
N= 6,943
Exclude patients with histology other than adenocarcinoma or squamous cell carcinoma
N= 8,441
Exclude patients with previous or concurrent cancer excluding basal cell carcinoma of skin
N= 4,537
Exclude patients younger than 65 years of age at diagnosis
N= 4, 123
Exclude patients enrolled in Medicare with end stage renal disease
N= 2348
Exclude patients not enrolled in Part A and B Medicare
N= 927
Patients unable to be matched with Medicare claims
N= 2,541
Final number of patients included in study cohort
N= 12, 341
Figure 4. Flow diagram showing patient selection process
The final sample for this study included Caucasian, African American, and
Hispanic patients with Medicare coverage who were at least 65 years of age, and had
been diagnosed with stage IIIB or stage IV NSCLC. All patients had Part A and Part B
Medicare coverage at the time of diagnosis and continuously during their treatment.
The SEER-Medicare linked data set represents the 18 SEER registry areas only
and therefore only approximately represents the general population. Patients from the
SEER registry may not be representative of the general population in the United States
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diagnosed with NSCLC as some patient groups were underrepresented, such as African
Americans and Hispanics. Age and gender in the SEER-Medicare dataset generally are
representative of the general population.
Results
Descriptive Statistics
The final number of patients who met the inclusion and exclusion criteria for the
study in these analyses was 12,341. The demographic variables were summarized by
race/ethnicity using frequency distributions. The results of this analysis are presented in
Table 2. The largest percent of patients (n = 2,929, 23.7%) were between 70 and 74
years of age, with those diagnosed at 85 years and older (n = 1,533, 14.5%) representing
the smallest group. There were slightly more male patients (n = 6,630, 53.7%), than
female patients (n = 5,711, 46.3%) included in the analysis. Most patients included in the
study were Caucasian (10,940, 88.6%), with 1,245 (10.1%) African American, and 156
(1.3%) Hispanic. The majority of the patients (72.3%) had stage IV metastatic disease
and 27.5% had stage IIIB disease. There were 3,398 patients (27.5%) presenting with
stage IIIB disease. The histology with the largest number of participants was
adenocarcinoma (72.3%), while 27.7% had squamous cell. Geographically the largest
percent of patients were from the West (37.6%), and lowest percent was in the Midwest
(13.4%).
Within race/ethnicity patient characteristics were fairly well balanced for
squamous cell histology, stage, and gender (table 2). Across race/ethnicity for
geographic location, 81.4% of Hispanics lived in the West compared to 39.0% of
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Caucasians and 20.6% of African Americans. Forty-five percent of African Americans
lived in the South, compared with 27.1% of Caucasians and 3.2% of Hispanics. There
were no Hispanics in the Midwest region. For age at diagnosis, race/ethnicity was fairly
well balanced for ages 65-69 and 70-74 years. Nearly one-quarter of African-Americans
(23.8%) were aged 75-79 years, closely followed by Caucasians (23.1%) and lastly,
Hispanics (10.9%). Hispanics were generally older than other racial/ethnic groups.
Nearly one-third of Hispanics (32.1%) were age 80-84 followed by nearly 20% of
Caucasians (19.4%) and lastly African Americans (14.2%). For patients age 85 and older
20.5% were Hispanic, 12.8% were Caucasians, and 8.2% were African American.
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Table 2
Clinical and Demographic Characteristics by Race/Ethnicity (N=12,341)
Characteristics

Caucasian
n =10,940

African American
n= 1,245

Hispanic
n =156

2322 (21.2)

335 (26.9)

32 (20.5)

70-74

2569 (23.5)

335 (26.9)

25 (16.0)

75-79

2531 (23.1)

296 (23.8)

17 (10.9)

80-84

2911 (19.4)

177 (14.2)

50 (32.1)

85 and older

1399 (12.8)

102 (8.2)

32 (20.5)

Gender, N (%)
Male

5822 (53.2)

710 (57.0)

98 (62.8)

Female

5118 (46.8)

535 (43.0)

58 (37.2)

Stage, N (%)
IIIB

3005 (27.5)

356 (28.6)

37 (23.7)

IV

7935 (72.5)

889 (71.4)

119 (76.3)

7944 (72.6)

869 (69.8)

115 (37.7)

2996 (27.4)

376 (30.2)

41 (26.3)

2256 (20.6)

226 (18.2)

24 (15.4)

Midwest

1459 (13.2)

198 (15.9)

0 (0)

South

2962 (27.1)

565 (45.4)

5 (3.2)

West

4263 (39.0)

256 (20.6)

127 (81.4)

Age at Diagnosis, N (%)
65-69

Histology
Adenocarcinoma
Squamous Cell
Geographic Location
N (%)
Northeast
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Patient treatment in accordance to NCCN treatment guidelines was crosstabulated by race/ethnicity. An analysis was also cross-tabulated by gender, age, stage of
disease, and geographic location within race/ethnicity and these analyses are presented in
Tables 4-8. The total number of participants’ treated according to NCCN guidelines by
race/ethnicity are shown in Table 3.

Table 3
Treatment According to NCCN Guidelines by Race/Ethnicity (N = 12, 341)
Treatment According to NCCN Guidelines
Ethnicity

Caucasian
n

African American

%

n

%

Hispanic
n

%

Yes
No

858
10082

7.9
92.1

78
1167

6.3
93.7

7
149

4.5
95.5

Total

10940

100.0

1245

100.0

156

100.0

A total of 10,940 Caucasians were included in the analysis, of which 858 (7.9%) were
treated according to the NCCN guidelines, followed by 78 African Americans (6.3%),
and 7 (4.5%) Hispanics.
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Table 4
Treatment According to NCCN Guidelines by Stage of Disease and Race/Ethnicity
(N = 12, 341)
Stage
of disease

Stage IIIB

Stage IV

Treatment
to
guidelines

Caucasian

Hispanic

Total

n (%)

African
American
n (%)

n (%)

n

Yes

398 (13.2)

45 (12.6)

2 (5.4)

445 (13.1)

No

2607 (86.8)

311 (87.4)

35 (94.6)

Yes

460 (5.8)

33 (3.7)

5 (4.2)

498 (5.6)

No

7475 (94.2)

856 (96.3)

114 (95.8)

8,445 (94.4)

2,953 (86.9)

When evaluating stage of disease (Table 4), there were fewer patients with stage
IIIB disease than stage IV disease. Of the total 3,398 patients with stage IIIB disease,
445 patients (13.1%) were treated according to the NCCN guidelines, including 13.2% of
Caucasians followed by African Americans (12.6%) and Hispanic patients (5.4%). Of
the total 8,943 patients with stage IV disease, 498 (5.6%) were treated according to the
guidelines. There were 460 Caucasian patients (5.8%) with stage IV disease treated
according to the guidelines, 5 Hispanic patients (4.2%), and 33 African Americans (3.7)
treated according to the guidelines.
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Table 5
Treatment According to the NCCN Guidelines by Histology and Race/Ethnicity
(N= 12,234)
Histology

Caucasian
n (%)

African
American
n (%)

Hispanic
n (%)

Total
n

560 (7.0)

55 (6.3)

5 (4.3)

620

No

7384 (93.0)

814 (93.7)

110 (95.5)

8308

Squamous
Yes

298 (9.9)

23 (6.1)

2 (4.9)

323

No

2698 (90.1)

353 (93.9)

39 (95.1)

3090

Adenocarcinoma
Yes

For histology (Table 5), there were a total of 3,413 patients diagnosed with
squamous cell lung cancer, with 323 (9.5%) receiving treatment according to NCCN
guidelines. Among the total 8,928 patients who had adenocarcinoma, 620 (6.9 %) were
receiving treatment according to NCCN guidelines. Seven percent of Caucasians with
adenocarcinoma were treated according to the guidelines, followed by African Americans
(6.3%), and Hispanics (4.3%). Approximately 10% of Caucasians with squamous cell
carcinoma were treated according to the guidelines (9.9%), followed by African
Americans (6.1%), and Hispanics (4.9%).
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Table 6
Treatment According to NCCN Guidelines by Age and Race/Ethnicity (N = 12, 341)
Age at
diagnosis
(years)

Treatment
to
guidelines

Caucasian

Hispanic

Total

n (%)

African
American
n (%)

n (%)

n (%)

65-69

Yes

258 (11.1)

32 (9.6)

3 (9.4)

293 (10.9)

70-74

Yes

233 (9.1)

17 (5.1)

1 (4.0)

251 (8.6)

75-79

Yes

214 (8.5)

21 (7.1)

0 (0)

235 (8.3)

80-84

Yes

115 (5.4)

8 (4.5)

3 (6.0)

126 (5.4)

85 +

Yes

38 (2.7)

0 (0)

0 (0)

38 (2.5)

Table 6 shows the number and percent of patients in each age group by
race/ethnicity treated according to the guidelines as a percent of the total number of
patients for the age group. There were a total 2,686 patients in the age group 65-69 of
which 10.9% were treated according to the NCCN guidelines. Eleven percent of
Caucasians in the 65-69 year age group were treated according to the guidelines,
followed by 9.6% of African Americans, and 9.4% of Hispanics. For patients aged 70-74
years, a total of 251 patients (8.6%) were treated according to the guidelines, including
9.1% of Caucasians, 5.1 % of African American patients, and 4.0 % of Hispanics. A total
of 235 patients (8.3%) aged 75-79 treated according to the NCCN guidelines. There were
214 Caucasian patients (8.5%) and 21 (7.1%) African Americans treated appropriately.
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There were no Hispanic patients in the 75-79 aged group treated according to guidelines.
In the 80-84 year aged group there were a total of 126 patients (5.4%) treated according
to guidelines; 5.4% of Caucasians, 6.0% of Hispanics, and 4.5% of African American.
The lowest percent of patients treated according to the guidelines were in the 85 and
older age group (2.5%) and were all Caucasians.

Table 7
Treatment According to NCCN Guidelines by Gender (N = 12, 341)

Treatment
to the
guidelines

Caucasian

Male
Female

Gender

Hispanic

Total

n (%)

African
American
n (%)

n (%)

n (%)

Yes

476 (8.2)

52 (7.3)

6 (6.1)

534 (8.1)

Yes

382 (7.5)

26 (4.9)

1 (1.7)

409 (7.2)

Table 7 represents the percentage of male and female patients treated according to
the guidelines with each race/ethnic group. Of the total 6, 630 males, 534 (8.1%) were
treated in accordance with the NCCN guidelines and of the total 5,711 females 409
(7.2%) were treated according to the guidelines. Within each racial/ethnic group a lower
percentage of females than males received guideline appropriate treatment. There were
382 (7.5%) female Caucasian patients who received guideline appropriate treatment
followed by 26 (4.9%) female African American patients, and 1 (1.7%) female Hispanic
patient that received treatment according to the guidelines. In comparison, 8.2%
Caucasian males were treated according to the guidelines followed by 7.3% of African
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American males, and 6.1% of Hispanic males that received treatment according to the
NCCN guidelines.

Table 8
Treatment According to NCCN Guidelines by Region and Race/Ethnicity (N= 12, 234)
Geographic
region

Treatment to
Guidelines

Caucasian

Hispanic

Total

n (%)

African
American
n (%)

n (%)

n (%)

Northeast

Yes

183 (8.1)

14 (6.2)

1 (4.2)

198 (7.9)

Midwest

Yes

134 (9.2)

8 (4.0)

0 (0)

142 (8.6)

South

Yes

242 (8.2)

41 (7.3)

0 (0)

283 (8.0)

West

Yes

299 (7.0)

15 (5.9)

6 (4.7)

320 (6.9)

Table 8 shows the percent of patients by region within each racial/ethnic group
who were treated according to the NCCN guidelines as a percent of the total number of
patients in each region. There were a total of 198 (7.9%) patients in the Northeast, 142
(8.6%) patients in the Midwest, 282 (8.0%) patients in the South, and 320 (6.9%) patients
in the West received treatment according to the guidelines. Across all regions a larger
percent of Caucasians received appropriate treatment to the guidelines as compared to
African American and Hispanic patients. There were no Hispanic patients in the
Midwest or South that received treatment according to the NCCN guideline.
Logistic Regression Overview
A regression analysis was conducted that included all independent and covariate
variables entered simultaneously into the analysis (Table 9). The dependent variable was
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treatment according to the NCCN guidelines. The full regression model reveals there
was a significant difference between African Americans compared to Caucasians treated
according to the guidelines OR= .68[95% CI (.54, .88, p= .002)]. There was a 32%
decrease in the odds of African Americans being treated according to the guidelines.
There was not a statistically significant difference between Caucasians and Hispanics (p=
.373). The results of the full model show that as age increased the odds of being treated in
accordance to the guidelines decreased. The results of the full model show that age at
diagnosis was statistically significant for all age groups and had a negative correlation to
treatment. Results revealed that gender was not significant predictor OR = .92 (95% CI
[.80, 1.0, p = .210]).
Geographic region was associated with receiving treatment according the NCCN
guidelines; patients living in the West had lower odds OR = 0.82, (95% CI [.68, .99, p =
.036]) of receiving treatment according to NCCN guidelines as compared to patients in
the Northeast. The results of each logistic regression model are presented by and
categorized by stage of disease and histology (e.g., stage IIIB adenosquamous, stage IV
adenocarcinoma, stage IV squamous cell) with comparisons by race/ethnicity, Caucasian
compared to African American and Hispanics and African Americans compared to
Hispanics. (Tables 10-15)
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Table 9
Full Logistic Regression with all Variables and Covariates for Treatment According to
the NCCN Guidelines
B

Wald

OR

CI lower

CI upper

p-value

-.28

128.55
9.47

.75

.63

.90

.002

75-79

-.36

15.22

.70

.58

.83

<.000

80-84

-.88

59.63

.42

.34

.52

<.000

85+

-1.70

92.27

.18

.12

.25

<.000

Female

-.098

1.57

.92

.80

1.06

.210

Age Group
70-74

Race/Ethnicity
African American
Hispanic

9.86
-.378

9.15

.68

.54

.88

.002

-.35

.79

.70

.33

1.53

.373

Geographic Location

6.77

Midwest
South

.03
-.10

.07
1.10

1.03
.90

.82
.74

1.30
1.10

.798
.295

West

-.20

4.41

.82

.68

.99

.036

.27

9.31

1.25

1.08

1.45

.002

-1.00

203.91

.37

.32

.42

<.000

Squamous cell
Stage IV
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Research Question and Hypotheses
In the sections that follow, pair wise comparisons for the racial/ethnic groups
within strata defined by stage of disease and histology are provided.
Caucasians Compared to African Americans
The first pair wise comparison was between Caucasians and African Americans.
Stage IIIB Adenosquamous Carcinoma
Of the 3398 patients with stage IIIB NSCLC, 2,953 patients were not treated
according to the NCCN guidelines, and 455 patients were treated according to the NCCN
guidelines included in this model.
There was not a significant difference between Caucasians and African American
patients treated per the guidelines OR= .812 (95% CI [.58, 1.137, p= .225]). The odds of
females being treated according to the guidelines were not significantly different from
males, OR = .93 (95% CI [.76, 1.14, p = .478]). The odds were less that patients age 85
and older were treated according to the guidelines (OR= .225, [95% CI .14, .35, p=
0.000]), when compared to patients’ aged 65 to 69. Patients living in the West had 30%
lower odds of receiving treatment according to the guidelines when compared with those
in the Northeast OR= .699 (95% CI [.51, .90, p= .008]). Patients in the Midwest had
23% higher odds of not being treated according to NCCN guidelines OR=1.23 (95% CI
[.92, 1.78, p= .150]) compared to those living in the Northeast.
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Table 10
Results of Logistic Regression of Caucasian Patients Compared to African American
Patients within Stage IIIB Adenosquamous Carcinoma
Wald
Age Group
65-69

OR

CI lower

CI upper

p-value

55.38

70-74

2.62

.79

.59

1.05

.106

75-79

1.89

.82

.62

1.09

.169

80-84

21.02

.47

.34

.65

.000

85+

42.08

.22

.14

.35

.000

Geographic Region
Northeast

18.12

Midwest

2.07

1.23

.917

1.78

.150

South

.108

.95

.715

1.27

.743

6.99

.68

.510

.90

.008

1.47

.812

.58

1.137

.225

.50

.93

.76

1.14

.478

West
Race/Ethnicity
Caucasian
African American

2.186

Gender
Female
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Stage IV Adenocarcinoma
Table 11 presents results for Caucasian patients compared with African American
patients with stage IV adenocarcinoma. There were 386 patients treated according to the
NCCN guidelines and 6,263 patients were not treated according to the guidelines.
A comparison of Caucasian and African Americans with stage IV
adenocarcinoma revealed race/ethnicity was statistically significant for predicting
treatment OR = 625(95% CI [.417,938 p= .023]). The odds of African Americans with
stage IV adenocarcinoma being treated according to the guidelines decreased by nearly
38% OR= .625, (95% CI [.47, .938 p= .023). Age at diagnosis within all age groups was
statistically significant for treatment according to the guidelines. As age increased, the
odds of treatment according to the guidelines decreased for all age groups as compared to
patients 65-69 years of age. Geographic location and gender were not significant
predictors of treatment according to the guidelines.
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Table 11
Logistic Regression in Caucasian Patients Compared to African American Patients with
Stage IV Adenocarinoma
Wald

OR

CI lower

Age Group
Age 65-69
Age 70-74

64.81
8.88

.67

.52

.87

.003

Age 75-79

15.02

.58

.44

.76

.000

Age 80-84

30.97

.38

.27

.53

.000

Age 85+

38.92

.10

.05

.21

.000

Gender
Female

1.09

.90

.73

1.10

.296

Race/Ethnicity
Caucasian

5.85
5.16

.625

.417

.938

.023

Midwest

.02

1.03

.71

1.49

.886

South

.05

.97

.71

1.31

.828

West

.08

1.04

.79

1.38

.775

African American

CI upper

p value

Geographic Location
Northeast

Stage IV Squamous Cell Carcinoma
Results of the pair wise analysis with Caucasian patients compared to African
American patients with stage IV squamous cell carcinoma are shown in Table 12. Of the
2,294 patients with stage IV squamous cell carcinoma, 112 patients received treatment
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according to the NCCN guidelines and 2, 182 patients did not receive treatment
according to the NCCN guidelines.
Race/ethnicity overall was significant for treatment between Caucasians and
African Americans according to the guidelines in patients with stage IV squamous
carcinoma of the lung. African Americans had a nearly 59% lower odds of being treated
according to NCCN guidelines when compared to Caucasians, OR = .413 (95% CI [.178,
.957 p= .039]). Age at diagnosis was statistically significant in predicting treatment
according to NCCN guidelines for the age groups 80 to 84 OR = .44 [95% CI (.221, .876
p= 0.19)] and 85 years and older OR= .304 [95% CI (.12, .80. p= .016)] were the only
age groups that were statistically significant. These two age groups had lower odds of
being treated according to the guidelines than patients’ age 65 to 69. Patients’ age 70 to
74 had a 12% higher odds of receiving treatment according to the guidelines although this
result was not statistically significant (p = .650) when compared to Caucasian patients.
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Table 12
Logistic Regression for Caucasian vs. African American Patients with Stage IV
Squamous Cell Carcinoma
Patient Characteristic

Wald

OR

CI lower

CI upper

p value

13.56
.205

1.12

.68

1.85

.650

.58

.81

.42

1.39

.448

5.46

.44

.22

.88

.019

5.84

.30

.12

.80

.016

1.19

.80

.53

1.20

.276

Age Group
Age 65-69
Age 70-74
Age 75-79
Age 80-84
Age 85+
Gender
Female
Geographic Location
Northeast

4.70

Midwest

3.56

.52

.26

1.03

.059

South

2.14

.68

.41

1.14

.144

West

3.08

.62

.37

1.06

.079

.413

.178

.957

.039

Race/Ethnicity
Caucasian
African
American

4.53
4.25
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Comparison of Caucasians and Hispanics
The second hypothesis was to determine if Caucasian and Hispanic patients with
NSCLC were equally likely to be treated in accordance with the NCCN treatment
guidelines within stage and histology strata. The pair wise comparisons are shown in
Tables 13-15.
Stage IIIB Adenosquamous Carcinoma
Among patients with Stage IIIB adenosquamous carcinoma, 445 were treated
according to the NCCN guidelines and 2,953 patients were not treated using these
guidelines. The results are in Table 13.
Race/ethnicity was not a significant contributor in predicting treatment according
to the guidelines. A non-statistical difference was found in the odds of being treated in
accordance to the guidelines for Caucasians as compared to Hispanics OR = .93 (95% CI
[.62, 1.39, p =0.38]). However, these results should be interpreted with caution due to the
small number of Hispanics patients compared to Caucasian patients.
Age at diagnosis was significant in predicting treatment per the NCCN
guidelines. Patients in age group 80 to 84 had a 53% lower odds of being treated
according to the guidelines as compared to patients aged 65-69 OR = .47 (95% CI [.34,
.65, p = .000]). Patients age 85 and over had 73% lower odds of receiving treatment
according to the guidelines as compared to patients age 65-69. However, because of the
small sample size, caution should be taken when interpreting these results.
Geographic location was statistically significant in this model for patients living
in the West. For patients in the West, odds of being treated according to the guidelines
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was 31% lower than patients living in the Northeast, OR = .69 [95% CI (.51, .90, p =
.008)].
Table 13
Logistic Regression for Hispanic Patients Compared with Caucasian Patients with Stage
IIIB Adenosquamous
Patient Characteristic
Age Group

Wald

OR

CI lower

CI upper

p value

Age 65-69
Age 70-74

55.38
2.62

.79

.59

1.05

.106

Age 75-79

1.89

.82

.62

1.09

.169

Age 80-84

21.02

.47

.34

.65

.000

Age 85+

42.08

.23

.14

.35

.000

.50

.93

.76

1.14

.478

Caucasian

.744

.93

.62

1.39

.38

Hispanic

2.19

2.07

1.28

.92

1.78

.150

South

.11

.95

.72

1.27

.743

West

6.99

.68

.51

.90

.008

Gender
Female
Race/Ethnicity

Geographic Location
Northeast
Midwest

18.12
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Stage IV Adenocarcinoma
A pair wise test comparing Caucasians and Hispanics being equally treated
according to the NCCN guidelines are shown in Table 14. Included in this analysis were
386 patients who were treated according to the NCCN guidelines and 6,263 patients who
did not receive treatment according to the NCCN guidelines.
Race/ethnicity, gender, and geographic location were not significant predictors of
treatment to the guidelines. A significant difference in the odds was not found for
Hispanics and Caucasian patients with stage IV adenocarcinoma OR= 1.68 (95% CI
(.523, 5.41, p = .383)]. This result may be due to the small number of Hispanic patients
in the cohort. Because few Hispanics with stage IV adenocarcinoma were included in this
model compared to Caucasians, drawing conclusions is difficult.
Age at diagnosis for all age groups was the only variable that was statistically
significant in predicting treatment in accordance to NCCN guidelines in patients with
stage IV adenocarcinoma compared to patients age 65-69. Patients age 85 and older had
the lowest odds of being treated according to the guidelines as compared to patients age
65 to 69 OR = .10 [95% CI (.05, .21, p = .000)]. As age increased, the odds of treatment
to the guidelines decreased.
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Table 14
Logistic Regression for Hispanic Patients Compared to Caucasian Patients with Stage IV
Adenocarcinoma
Patient Characteristic
Age Group
Age 65-69

Wald

OR

CI lower

CI upper

p value

64.81

Age 70-74

8.88

.67

.52

.87

.003

Age 75-79

15.02

.58

.44

.76

.000

Age 80-84

30.96

.38

.37

.53

.000

38.92

.10

.05

.21

.000

1.09

.90

.72

1.10

.296

.76

1.68

.52

5.41

.38

Age 85+
Gender
Female
Race/Ethnicity
Caucasian
Hispanic

5.85

Geographic Location
Northeast

.338

Midwest

.020

1.03

.71

1.49

.886

South

.047

.97

.71

1.31

.828

West

.082

1.04

.79

1.38

.775

Stage IV Squamous Cell Carcinoma
Among the 2,294 patient treated with stage IV squamous cell carcinoma, 112
were treated according to NCCN guidelines and 2,182 patients were not treated
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according to the guidelines. The pair wise results for Hispanic patients compared to
Caucasian patients with stage IV squamous cell carcinoma showed race/ethnicity
was not a significant predictor of treatment according to NCCN guidelines. No valid
conclusions could be drawn regarding race/ethnicity, age, or geographic location for
treatment, as only 33 Hispanic patients with stage IV squamous cell carcinoma were
included in the analysis compared to 2,006 Caucasian patients.
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Comparison of Hispanics and African Americans
The pair wise comparison for Hispanic and African American patients with
squamous cell carcinoma is shown in Table 15. Because Hispanics (n=33) are a smaller
group in this study than African Americans (n= 255), the analysis was conducted with
Hispanics as the reference group. Results of the analysis revealed a non-statistical
difference in treatment between Hispanics and African American patients OR = .29 [95%
CI [(.05, 1.54, p = .145)]. Because of the small number of Hispanic patients with stage IV
squamous cell lung cancer, drawing any conclusions regarding treatment comparisons in
accordance to the guidelines is difficult.
Age at diagnosis in all age groups was the only significant predictor for treatment
in accordance in NCCN guidelines and indicated that as age increased the odds of being
treated according to NCCN guidelines decreased. Only patients in the West showed a
significant difference in treatment according to the guidelines OR = (95% CI [.67, .98, p=
0.04]).
The comparison of Hispanic and African American patients with stage IV
adenocarcinoma, revealed there was not a statistical difference in the odds of treatment
OR=1.05 (95% CI [.307, 3.59, p=. 936]) and that both groups were closely treated to the
guidelines. However, due to the small sample size conclusions cannot be drawn
regarding treatment according to NCCN guidelines for Hispanic and African American
patients.
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Table 15
Logistic Regression of Hispanic Patients Compared to African American Patients with
Stage IV Squamous Cell Carcinoma
Patient Characteristics

Wald

OR

CI lower

CI upper

p value

Age
Age 65-69

128.5

Age 70-74

9.4

.75

.63

.90

.00

Age 75-79

15.21

.67

.58

.83

.00

Age 80-84

59.63

.42

.38

.52

.00

Age 85+

92.26

.13

.13

.26

.00

Gender
Female

1.57

.91

.80

1.05

.21

Race/Ethnicity
Hispanic

4.53
.287

.053

1.53

.14

.66

1.030

.81

1.29

.79

South

1.97

.90

.74

1.09

.29

West

4.41

.92

.67

.98

.03

African
American
Geographic Location
Northeast
Midwest

2.12

6.76
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Post Hoc Analysis
Because the number of African American and Hispanic patients individually was
small, their numbers were combined and a new racial/ethnic group was created and titled
other race/ethnicity. The other race/ethnicity group contains 1401 patients.
A post hoc full model regression analysis was performed (Table 16). The results
showed the odds of patients in the other race/ethnicity were less likely to be treated
according the to guidelines than Caucasians. There was a 31% reduction in the odds of
being treated according to the guidelines OR= 0.69, (95% CI [.534, .869, p= .002]). Age
at diagnosis was significant in all age groups. As age increased, the odds of treatment
according to the NCCN guidelines were less likely. Gender is not statistically
significantly associated with treatment according to the NCCN guidelines in the post hoc
analysis. There was a statistically significant difference in treatment between patients in
the West as compared to patients in the Northeast OR= .818 (95% CI [.678, .987, p=
.036)].
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Table 16
Post Hoc Logistic Regression of Caucasian Patients Compared to Other Race/Ethnicity
Patient
Characteristic

Wald

OR

CI lower

CI upper

p value

Age at Diagnosis
65-69

128.660

70-75

9.468

.754

.63

.90

.002

76-79

15.225

.695

.58

.83

.000

80-84

59.671

.421

.34

52

.000

85 +

92.271

.182

.13

.26

.000

1.57

.916

.799

1.050

.209

9.850

.687

.543

.869

.002

Gender
Female
Race/Ethnicity
Other
Region
Northeast

6.782

Midwest

6.5
1.104
4.408

1.030
.90
.818

.82
.742
.678

1.296
1.094
.987

0.80
0.30
.036

203.936

.37

.32

.423

.000

9.309

1.253

1.084

1.449

.002

South
West
Stage
IV
Histology
Squamous Cell
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Summary
The purpose of this population-based cohort study was to determine the likelihood
of elderly patients with stage IIIB or IV NSCLC adenocarcinoma or
squamous cell carcinoma being equally treated according to the NCCN guidelines. For all
research hypotheses, a binary logistic regression model was conducted controlling for
covariates. Overall, the odds of treatment according to the NCCN guidelines was poor
with 92.4% of patients not likely to receive treatment according to the guidelines and
7.6% of patients likely to receive treatment according to the guidelines. The results were
mixed for the likelihood of being equally treated according to the guidelines for
race/ethnicity.
The first hypothesis tested that Caucasians and African Americans with stage IIIB
adenosquamous carcinoma were equally likely to the treated according to NCCN
guideline was not retained. For Caucasian and African American patients with stage IV
adenocarcinoma and stage IV squamous cell carcinoma, the null hypothesis (H0) was
rejected. Caucasian and African American patients were not equally treated according to
the guidelines. The odds of African American patients being treated in accordance to the
guidelines was less than for Caucasians.
The odds of Caucasian and Hispanic patients being equally treated according to
the NCCN guidelines revealed no statistically significant difference; therefore, the null
hypothesis was retained. However, caution should be taken when evaluating the data,
due to the small number of Hispanic patients in this cohort.
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The odds of Hispanics and African Americans being equally treated according to
NCCN guidelines indicated they were equally likely to be treated according to the
guidelines while controlling for other variables. When other factors that could affect
treatment were considered, age at diagnosis was significant in all analyses, revealing that
older patients were less likely to be treated according to the NCCN guidelines when
compared to patients age 65-69. No differences were found in the odds of treatment
according to NCCN guidelines between males and females within stage and histology for
all models.
For all patient groups, patients with adenocarcinoma were less likely to receive
treatment according to the guidelines as compared to patients with squamous cell
carcinoma. Stage IV patients were less likely to be treated according to the guidelines
than Stage III patients. In a post hoc analysis, when African American and Hispanic
patients were combined to create a new race/ethnicity category, other races, there was a
statistical difference between Caucasians and other races in treatment according to the
NCCN guidelines, therefore the null hypothesis was not retained. Chapter 5 discusses the
interpretation of the results, the limitations, recommendations for future research, and
implications.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this population-based cohort study was to evaluate if patients age
65 years or older with stage IIIB or stage IV adenocarcinoma or squamous cell histology
NSCLC were equally treated according to the NCCN guidelines. Specifically, this
research was undertaken because few studies on cancer, including lung cancer, have
looked at treatment adherence based on national clinical guidelines. National guidelines
for specific patient diagnoses are used to provide patient treatment recommendations
based on efficacy, toxicity, and then cost when efficacy and toxicity are equal. Failure to
comply with the NCCN guidelines or other national guidelines for cancer treatment may
compromise patient outcomes and increase the cost of care. Based on the results of this
study, race and age at diagnosis contributed to NSCLC treatment in accordance with the
NCCN guidelines.
Interpretation of Findings
The current analysis demonstrated that for patients with stage IV adenocarcinoma,
the odds of African American patients being treated according to clinical guidelines were
38% less than for Caucasians patients with the same diagnosis. Among patients with
stage IV squamous cell carcinoma, African American patients had 59% lower odds than
Caucasian patients of being treated according to the NCCN guidelines. In the post hoc,
when race/ethnicity was evaluated, there was a 31% reduced chance of patients of other
race/ethnicity being treated according to the guidelines compared to Caucasians. Despite
uniform health insurance coverage, the odds of being treated according to the clinical
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guidelines vary. The decision to treat elderly lung cancer patients is complex. In this
analysis, age at diagnosis was a significant factor for appropriate treatment. There was an
inverse relationship between age and treatment according to the guidelines. These results
are similar to the results from previous studies (Earle et al. 2000; Potosky et al., 2004).
Differences between Caucasian and African American patients with stage IIIB
disease were not statistically significant; possibly due to the small probability that
patients with stage IIIB cancer live longer than those with stage IV and can actually be
cured in some cases with aggressive treatment (Simone, 2013). The lack of a significant
difference between Caucasian and Hispanic patients, and between African American and
Hispanic patients with stage IIIB or stage IV disease suggests that patients are equally
likely to be treated according to the guidelines, and this is in agreement with previous
studies (Goulart et al. 2012). However, these results can be difficult to interpret, as the
number of African American and Hispanic patients in this study was insufficient to
predict a difference accurately. The smaller number of Hispanic patients is a reflection of
the lower incidence of smoking rates and lung cancer in Hispanic patients (Saeed et al.,
2012). In addition, Hispanics with NSCLC tend to have more bronchiolalveolar
histology than Caucasian or African American patients (Saeed et al. 2012).
Bronchiolalveolar carcinoma, a subtype of adenocarcinoma of the lung, represents
approximately 4% of NSCLC (Read, Page, Tierney, Piccirillo, & Govindan, 2004).
Bronchioalveolar histology was not included in this study because most of these tumors
are detected at an early stage and are usually resected (Maza, Meernik, Jeon & Cote,
2015).
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Because little data is available on regional differences in the treatment of patients
with cancer, I examined whether there were differences in adherence to NCCN treatment
guidelines in NSCLC. This study revealed that patients with stage IIIB NSCLC living in
the West were less likely to be treated according to the guidelines than patients in the
Northeast. This difference may be due to more Hispanics living in the West as compared
to the Northeast and regional differences among patients and physicians in beliefs
regarding the treatment of advanced NSCLC. Hirth et al. (2015) noted differences in
treatment according to geographic location primarily between the Northeast and the West
regions. However, they found that these differences were poorly understood and might
not be able to be generalized in all settings due to variations in barriers to using
guidelines. A paucity of data is available about whether treatment is more aggressive in
one region than another, or whether physician beliefs regarding lung cancer treatment
differ across regions. Regional differences in the adherence to guidelines for the
treatment of prostate cancer, colon cancer, and rectal cancer were found in Texas, and the
investigators found that the differences within the state may be due to some regions being
more aggressive with treatment than other region. Other reasons may be patient medical
characteristics (Ho et al., 2016). Makarov et al. (2012) found regional differences in
cancer imaging among the SEER regions and that regions with high levels of appropriate
imaging also had high levels of inappropriate imaging. The reasons for these differences
were poorly understood and may go beyond competition between health facilities
(Makarov et al, 2015). Understanding specific patterns of geographic variation may need
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to be evaluated at the zip code, county, and hospital level and not the larger regional
level, as in the present study.
Several studies have shown that factors associated with a variation in general
cancer practice guideline compliance, including the NCCN guidelines, include (a) age,
(b) comorbidities, (c) insurance type, (d) institution, (e) region, (f) lack of physician
awareness of guidelines, (g) lack of physician agreement with guidelines, and (h)
physician time and resources (Goldberg, Akard, Dugan, Faderl, & Pecora, 2015; Ho et
al., 2016). Ho et al. (2016) found that differences in the treatment of colon, prostate, and
pancreatic cancer according to guidelines across Texas could be attributed to physician
referral patterns, patient age, gender, being Black, and living in a lower income area.
The median age of patients in this analysis was 75-79, slightly older than patients
diagnosed with lung cancer overall. Data from the SEER database showed individuals 80
years and older represent approximately 17% of lung cancer patients in the United States
(Altundag et al., 2007; Chen et al., 2016; Owonikoto et al., 2007). In this study, I found
that age at diagnosis was a major contributor in determining treatment according to the
NCCN guidelines. Differences in treatments were observed between the patient age
groups 75-79, 80-84, and over 85 years of age, as compared with patients 65-69 years for
all groups. As age increased, the odds of patients being treated according to the NCCN
guidelines decreased, which was similar to findings reported in other studies (Boland et
al. 2013; Wang et al, 2011). This difference may be due to the patient age, patient
comorbidities, and/or treatment effects/toxicity. Even with comorbidities, older patients
were able to tolerate chemotherapy. Chen et al (2016) found that 7.9% of octogenarians
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received chemotherapy and Potosky et al. (2004) found that 21% of octogenarians with
stage III NSCLC and 16% with stage IV NSCLC received recommended lung cancer
treatment. More recently, Cassidy et al. (2017) reported that patients with stage IIIB
NSCLC, adenocarcinoma histology, advancing age, female gender, and who are Black
received no treatment for their NSCLC. Researchers at the Association of the British
Pharmaceutical Industry (ABPI) have shown that a patient’s chronological age might
differ from their biological age, which was based on an individual’s functional capacity,
and could affect receipt of appropriate treatment (ABPI, 2012). Patient age was found to
be a major influential factor in the decision of how physicians treated a patient, in
addition to performance status (Foster et al., 2010). A retrospective study from M. D.
Anderson Cancer Center indicated that select patients with good performance status, 80
years and older, were able to tolerate standard chemotherapy and outcomes were similar
to younger patients (Altundag et al., 2007). Because limited information is available
from clinical trials on the use of cancer therapies in patients 70 years and older, further
research is warranted.
Maintaining quality of life is an important consideration for patients receiving
lung cancer treatment. Tradeoffs exist between side effects of treatment and clinical
benefits. These tradeoffs vary among patients depending on how they value time. Some
patients may prefer to avoid side effects, while other patients may consider side effects to
be manageable and feel that benefits of treatment may offset the side effects. Some
patients may not want to receive aggressive treatment if the gain in life is not significant.
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Quality of life for patients and the family should be considered and discussed with the
physician.
Comorbidities, such as heart disease, diabetes, pulmonary diseases, hypertension,
decreased renal function, alterations in drug metabolism, and “polypharmacy,” are
common in elderly patients and can influence treatment decisions (Chen et al. 2016).
Although elderly patients tend to have greater co-morbidity that contributes to increased
toxicities, age alone should not prevent an elderly lung cancer patient from receiving
treatment (NCCN Senior Adult Oncology, 2014; Tas, Ciftci, Kilic, & Karabulut, 2013;
Wang et al, 2011). Because the increased risk for toxicity from chemotherapy or
radiation and co-morbidities decrease the likelihood of completing all treatment cycles,
physicians might decide not to treat a patient according to clinical treatment guidelines
(Chen et al., 2016). In some instances, the patient or family members may request
treatment discontinuation. The NCCN guidelines recommend physicians consider comorbidities when recommending cancer treatments for the elderly (NCCN Senior Adult
Oncology, 2014). Wang et al. (2011) found that when age and co-morbidity were both
taken into account, elderly patients without co-morbidities were treated less frequently
than younger patients with co-morbidities. They also noted that patients over 85 were
treated less frequently than patients 75 and younger (Wang et al, 2011). The NCCN
clinical guidelines recommend single agent chemotherapy to improve quality of life and
survival in patients 70 to 86 years of age (NCCN Senior Adult Oncology 2014; Tas et al.,
2013). Doublet chemotherapy showed benefits in patients 70-80 years of age that were
equivalent to patients younger than 70 years (Wang, Fuller, & Thomas, 2007). While the
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elderly cancer patient can be challenging to treat, they are also generally
underrepresented in clinical trials due to strict exclusion criteria. Therefore, additional
clinical trials specific for the elderly cancer patient are warranted to determine optimal
treatment (Tas et al., 2013).
Physician barriers to clinical practice guideline use in oncology have not been
studied extensively (Goldberg et al., 2015). Goldberg et al (2015) found resource
barriers, lack of familiarity, and lack of agreement with the NCCN guidelines for Chronic
Myelogenous Leukemia (CML) were reasons physicians did not following the guidelines.
They found that 84% of physicians were familiar with the NCCN guidelines for CML,
14% of physicians were familiar with the guidelines but did not use them in treating
patients, and 2% of physicians were not familiar with the NCCN guidelines for CML
(Goldberg et al., 2015). Most physicians reported the guidelines were difficult to find,
difficult to implement, offered few treatment options, and believed the guidelines
hindered their autonomy to practice medicine (Greenberg et al. 2015). A report by the
New England Healthcare Institute (2008) revealed physicians were more likely to follow
guidelines if they were relevant to their practice (NEHI, 2008).
Social cognitive theory was selected as the theoretical framework for this study as
it focuses on individual cognitive influences and incorporates the adoption of evidence
based practice changes. Lack of awareness and familiarity of guidelines can affect
physician knowledge and decisions to use the guidelines (Cabana et al., 1999). Fifty-six
percent of physicians from a variety of specialties were unfamiliar with clinical
guidelines and up to 91% did not agree with the guidelines. Self-efficacy and expected
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patient outcomes were found to be barriers to adopting treatment guidelines by physicians
(Cabana et al., 1999). Therefore, from a theoretical perspective, a lack of awareness and
lack of familiarity may affect physician knowledge of the NCCN guidelines.
Limitations of the Study
The SEER-Medicare linked data set is a large population-based database that
collects data for evaluating cancer care in the elderly in 97% of the United States
population 65 and older. The Medicare database is an administrative database designed
for tracking reimbursement claims. However, the database has its limitations when
applied for clinical research purposes, such as limited detailed diagnostic information,
inconsistency in the use of procedural coding, and difficulty in determining the timing of
events (Virnig & Madeira, 2012). The Medicare data are based on insurance claims data,
are input from tumor registrars, and are subject to errors. Because the SEER-Medicare
linked database is a population-based database the data are not subject to selection bias or
reporting bias. The limitations of the SEER-Medicare database relevant to this study are a
lack of information regarding a patient’s performance status that is used to measure how
a patients disease is progressing, treatment decisions, smoking status, patient comorbidities, weight loss, quality of life related to treatment, and reasons for not receiving
treatment or refusal of treatment. Because the population was limited to individuals with
Medicare (age 65 or older) the findings may not be generalized to a younger population
or patients with another type of insurance. As a retrospective study, an understanding of
causality cannot be determined.
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Recommendations for Future Research
By 2050 approximately 50% of the population is expected to be racial/ethnic
minority, thereby increasing the potential for disparities in cancer care (Gorin, Badr,
Krebs & Das, 2012). Although numerous studies have been conducted showing
disparities in the treatment of cancer, including lung cancer, most of these studies have
been in the earlier stages of the disease. Few studies, particularly in stage IIIB lung
cancer have been published that evaluate healthcare disparities in the Hispanic
population. Lung cancer treatment is complex and overcoming healthcare disparities is
complex and multifaceted, with several contributing factors including the age of the
patient, general decrease in performance status, and comorbidities. The patient and family
support system may also contribute to limited access of older patients to chemotherapy.
Patient health beliefs and attitudes can influence the healthcare practitioner treatment
behavior. The type of healthcare facility is among other contributing factors affecting
patient treatment. Developing trials specifically for the elderly and enrolling a diverse
racial/ethnic mix into clinical trials are needed to improve the understanding in treatment
differences. Based on findings of the present analysis, additional research is needed into
treatment differences according to patient age, geographic location, and compliance to
clinical treatment guidelines. In addition, future research should include patient
performance status; lifestyle factors, such as smoking status; and co-morbidities as these
influence patient treatment decisions.
Given the findings of this study, further prospective research evaluating specific
reasons why a patient is not treated consistent with the NCCN guidelines is warranted. Is
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noncompliance to the guidelines the physician’s decision or lack of familiarity of the
guidelines? Physicians have been found to be noncompliant with guidelines cross a
variety of medical specialties (Goldberg et al., 2015). Physician disagreement with the
guidelines, risk versus benefit of treatment, and patient/family decisions not to receive
recommended treatment have been found to influence compliance. However, it is
unknown if treatment was recommended by the physician and the patient refused
treatment, if the guideline treatment was offered to the patient, or for other reasons the
patient refused treatment. Additional research is needed on these factors focusing on the
healthcare system as it remains unclear what effect treatment differences reflect
individual patient decisions or healthcare system factors.
Oncology patient care is usually conducted with a team of physicians and
healthcare professionals guided by clinical practice guidelines or past experience to
provide the best care. Cancer care should be collaborative or a two-way street between
the healthcare professional and the patient. Physicians have limited time to spend with
each patient and having open communication with the patients and their families about
treatment plan and goals, toxicities of treatment, and understanding patient/family goals
and needs can improve outcomes. Patients and family should be aware that the NCCN
guidelines are available in lay persons terms, should become more involved in their own
care and should be willing to have a discussion with their physician about their treatment
goals. If a physician doubts a patient’s commitment to recommended treatment, another
easier treatment may be offered that is not in accordance to treatment guidelines (Martin,
Williams, Haskard & DiMatteo, 2005). Improving communication between the
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physician and the patient has been shown to improve patient compliance to treatment
(Zolnierek & Robin, 2009)
Accurate and complete race/ethnicity information needs to be captured within
large databases and registries. Encouraging patients, particularly African American and
Hispanics to participate in clinical trials could help in furthering an understanding of
treatment disparities on outcomes and is essential to formulate policy and design
programs to address the disparities. Additional education of healthcare professionals
around disparities and a better understanding of different racial/ethnic beliefs and cultural
differences are needed. Breaking down racial/ethnic differences may influence treatment
to the guidelines for the better. Additional research is needed to gain an understanding of
how treatment decisions are made within the healthcare system
Implications
Social Change
This research contributes to positive social change by providing support for a
better understanding of factors that might influence treatment according to the NCCN
guidelines. Increasing an understanding of racial disparities in the quality of NSCLC
care could help inform healthcare professional, policy makers, and public health
professionals to focus on decreasing disparities and improving care and cancer outcomes.
Basing public health initiatives, programs, research, and outcomes on evidence-based
guidelines data could lead to better public understanding of disease and treatment.
Educating patients about the availability of treatment guidelines and empowering
patients to take active roles in treatment decision process could go a long way to improve
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quality of life and outcomes in cancer treatment. Healthcare professionals need to take an
interest in what is important to the patient. While challenges to patient communication
exist partially due to the complexity of the disease and treatment, healthcare professionals
must continue to improve communication with patients and engage patients in their own
care.
Conclusions
In conclusion, the study findings revealed that race/ethnicity did not contribute
significantly to treatment according to the NCCN treatment guidelines. However, age at
diagnosis was a consistent contributor across all groups. In addition, regional differences
in treatment were found for some cancer patients. These findings provide a rationale for
the need to strengthen the clinical research in elderly lung cancer patients to understand
the best treatments for these patients and ways to improve compliance to the NCCN
clinical guidelines that might improve quality of life, outcomes to treatment, and help in
guiding the eradication of lung cancer. Further research is warranted to understand
physician lack of compliance to clinical guidelines and factors contributing to why
patients do not comply with physician treatment recommendations.
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